Compositions and methods for treating inflammatory bowel disease (IBD)

By targeting IBD patients without specific genetic or serological markers, the use of thiopurine drugs can be optimized to reduce adverse effects, enhancing treatment outcomes for IBD patients.

WO2024233362A1PCT designated stage expired Publication Date: 2024-11-14CEDARS SINAI MEDICAL CENT
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027767
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-05
Filing Date
2024-05-03
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Thiopurine drugs used to treat inflammatory bowel disease (IBD) often cause adverse effects in patients, and there is a need to identify patient populations that are less likely to experience these adverse events to improve treatment outcomes.

Method used

Administering thiopurine drugs to IBD patients who do not possess specific genetic variants or serological markers such as ANCA, NUDT15 variants, or HLA-DQA1*2, HLA-DRB1*7, HLADPB1*17, and HLAC-12*02, and using alternative therapeutic agents for patients with these markers to minimize adverse events.

Benefits of technology

This approach allows for the effective treatment of IBD with reduced risk of thiopurine-induced adverse events by tailoring therapy to individual genetic profiles, improving treatment efficacy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000047_0001
    Figure IMGF000047_0001
  • Figure IMGF000047_0002
    Figure IMGF000047_0002
  • Figure IMGF000048_0001
    Figure IMGF000048_0001
Patent Text Reader

Abstract

Provided herein are methods of treating an inflammatory bowel disease (IBD) in a subject by administering to the subject a thiopurine drug for the treatment of IBD, the subject not comprising an at risk genetic variant or serological marker. Also provided herein are related compositions, uses, system, and kits.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE (IBD)CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 500,498, filed on May 5, 2023, which is incorporated herein by reference in its entirety.BACKGROUND

[0002] Inflammatory bowel disease (IBD) has been treated with thiopurine drugs; however, a large number of patients treated with thiopurine drugs are known to experience adverse effects.SUMMARY

[0003] It is appreciated by the inventors that identifying relevant patient populations that respond favorably to thiopurine drugs for the treatment of IBD (e.g., by having a reduced likelihood of experiencing a thiopurine-induced adverse event) may represent an improvement over the state-of-the-art in treatment of subjects with IBD. Provided is a method of treating an IBD in a subject by administering to the subject a thiopurine drug for the treatment of IBD, the subject not comprising an at risk genetic variant or serological marker.

[0004] For example, in one aspect, provided herein is a method of treating an inflammatory bowel disease (IBD) in a subject, the method comprising: administering to the subject a therapeutically effective amount of a thiopurine drug for the treatment of IBD, wherein the subject: (a) does not comprise a serological marker comprising antinuclear cytoplasmic antibody (ANCA), antipseudomonas fluorescens- related protein (i2), or any combination thereof; (b) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (d) any combination thereof.

[0005] In another aspect, provided herein is a thiopurine drug for use in treating an IBD in a subject, wherein the subject: (a) does not comprise a serological marker comprising ANCA, i2, or any combination thereof; (b) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (d) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (e) any combination thereof.

[0006] In another aspect, provided herein is a therapeutic agent for the treatment of IBD other than a thiopurine drug for use in treating an IBD in a subject, wherein the subject comprises: (a) a serological marker comprising ANCA, i2, or any combination thereof; (b) a genotype comprising aNUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (d) any combination thereof.

[0007] In another aspect, provided herein is a method of determining whether a subject having IBD is likely to experience a thiopurine -induced adverse event, the method comprising: (a) detecting the presence of one or more of the following in the subject: (i) a serological marker comprising ANCA, i2, or any combination thereof; (ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iv) any combination thereof; and (b) determining a likelihood that the subject will experience a thiopurine -induced adverse event based, at least in part, on the presence of one or more of (i) - (iv) detected in the subject, wherein the likelihood is compared with a control subject having IBD but not having the presence of one or more of (i) - (iv) or having a lower risk as identified by another clinical method. In some embodiments, the method further comprises selecting a therapeutic agent for the treatment of IBD other than a thiopurine drug for the subject. In some embodiments, the method further comprises administering a therapeutically effective amount of a therapeutic agent for the treatment of IBD other than a thiopurine drug to the subject.

[0008] In another aspect, provided herein is a method of selecting a subject having IBD for treatment, the method comprising: (a) providing a sample from a subject having IBD to determine the presence of one or more of the following in the subject: (i) a serological marker comprising ANCA, i2, or any combination thereof; (ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iv) any combination thereof; (b) selecting a subject determined to comprise one or more of (i) - (iv); and (c) administering a therapeutically effective amount of a therapeutic agent for the treatment of IBD other than a thiopurine drug to the subject. In some embodiments, the subject is determined to comprise two or more of (i) - (iv), three or more of (i) - (iv), or all of (i) - (iv).

[0009] In another aspect, provided herein is a method of selecting a subject having IBD for treatment, the method comprising: (a) providing a sample from a subject having IBD to determine the presence of one or more of the following in the subject: (i) a serological marker comprising ANCA, i2, or any combination thereof; (ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iv) any combination thereof; (b) selecting a subject determined to not comprise any of (i) - (iv); and (c) administering a therapeutically effective amount of a thiopurine drug to the subject.

[0010] In some embodiments of any of the preceding aspects, the presence of the serological marker or the genotype is detected in a sample obtained from the subject. In some embodiments, the sample comprises blood, serum, plasma, sweat, hair, tears, urine, saliva, stool, or a combination thereof.

[0011] In some embodiments of any of the preceding aspects, the serological marker is detected by a method comprising an enzyme-linked immunosorbent assay (ELISA). In some embodiments, the method further comprises seropositivity or seronegativity of the serological marker, optionally wherein themeasuring the seropositivity or the seronegativity comprises calculating a percentage of a reference value from pooled sera obtained from a patient population diagnosed with IBD. In some embodiments, the measuring the seropositivity or the seronegativity comprises calculating a percentage of a reference value from pooled sera obtained from a patient population diagnosed with IBD.

[0012] In some embodiments of any of the preceding aspects, the genotype is detected by a method comprising detecting a nucleic acid sequence. In some embodiments, the detecting the nucleic acid sequence comprises performing quantitative polymerase chain reaction (qPCR), nucleic acid sequencing, or hybridization to immobilized nucleic acid sequences on a nucleic acid array.

[0013] In some embodiments of any of the preceding aspects, the therapeutic agent for the treatment of IBD other than a thiopurine drug comprises a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of tumor necrosis factor alpha (TNFa), an inhibitor of interleukin-23 (IL23), an inhibitor of integrin, an inhibitor of Sphingosine- 1 -phosphate receptor (S1PR), an inhibitor of TNF superfamily member 15 (TL1A), an inhibitor of CD30 ligand (CD30L), an inhibitor of Janus kinase 2 (JAK), an antagonist of interleukin -21 (IL21), or any combination thereof.

[0014] In some embodiments of any of the preceding aspects, the method further comprises administering one or more additional therapeutic agents to the subject. In some embodiments, the one or more additional therapeutic agents comprise a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of TNFa, an inhibitor of IL23, an inhibitor of integrin, an inhibitor of S 1PR, an inhibitor of TL1A, an inhibitor of CD30L, an inhibitor of JAK, an antagonist of IL21, or any combination thereof.

[0015] In some embodiments of any of the preceding aspects, the inhibitor of tumor necrosis factor alpha (TNFa) comprises adalimumab, infliximab, golimumab, certolizumab, or etanercept, or any combination thereof.

[0016] In some embodiments of any of the preceding aspects, the inhibitor of IL23 comprises ustekinumab, guselkumab, risankizumab, brazikumab, mirikizumab, tildrakizumab, or briakinumab, or any combination thereof.

[0017] In some embodiments of any of the preceding aspects, the inhibitor of integrin comprises etrolizumab, vedolizumab, natalizumab, or ontamalimab, or any combination thereof.

[0018] In some embodiments of any of the preceding aspects, the inhibitor of S 1PR comprises fmgolimod, siponimod, etrasimod, ozanimod, ponesimod, amiselimod, ceralifimod, or mocravimod, or any combination thereof.

[0019] In some embodiments of any of the preceding aspects, the inhibitor of TL1A comprises tulisokibart, RVT-3101 / PF-06480605, or duvakitug, or any combination thereof.

[0020] In some embodiments of any of the preceding aspects, the antagonist of IL21 comprises an antibody or an antigen-binding fragment thereof.

[0021] In some embodiments of any of the preceding aspects, the thiopurine comprises azathioprine, mercaptopurine, or thioguanine.

[0022] In some embodiments of any of the preceding aspects, the thiopurine-induced adverse event comprises one or more of bone marrow (BM) toxicity, leukopenia, pancreatitis, hepatotoxicity, gastrointestinal (GI) intolerance, arthralgia, rash, high fever, and hypersensitivity.

[0023] In another aspect, provided herein is a system for predicting a likelihood of a thiopurine -induced adverse event in a subject having IBD, the system comprising: (a) a genotyping device for determining genotype data of a subject with IBD; and (b) one or more computer processors operably coupled to the genotyping device, wherein the one or more computer processors are individually or collectively configured to perform operations comprising: (i) receiving the genotype data from the genotyping device; and (ii) identifying, in the genotype data, a genotype that is predictive of the likelihood of a thiopurine - induced adverse event. In some embodiments, the genotype comprises (i) a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (ii) HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iii) any combination of (i) and (ii).

[0024] In another aspect, provided herein is a kit for predicting a likelihood of a thiopurine-induced adverse event in a subject having IBD, the kit comprising: (a) one or more detection agents configured to bind or hybridize to (i) a polymorphism comprising aNUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566) or a proxy polymorphism in linkage disequilibrium (LD) therewith as determined with an r2 of at least 0.85, or a combination thereof, (ii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or a combination thereof, or (iii) multiple detection agents configured to bind or hybridize to both (i) and (ii); and (b) instructions for use of the detection agent to detect (i) the polymorphism or the proxy polymorphism in LD therewith, (ii) the genotype, or both (i) and (ii) in a sample obtained from the subject. In some embodiments, the kit further comprises a second detection agent configured to bind ANCA, i2, or a combination thereof, optionally wherein the second detection agent is an antibody; and instructions for use of the second detection agent to detect seronegativity or seropositivity of the ANCA, the i2, or a combination thereof in a sample from the subject. In some embodiments, the instructions further comprise instructions for predicting the likelihood of a thiopurine -induced adverse event in the subject.INCORPORATION BY REFERENCE

[0025] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.BRIEF DESCRIPTION OF THE DRAWINGS

[0026] A better understanding of the features and advantages of the present subject matter will be obtained by reference to the following detailed description that sets forth illustrative embodiments and the accompanying drawings of which:

[0027] FIG. 1 illustrates the dosage effect at DPB1* 17 on time from initiation of thiopurine drug treatment to development of pancreatitis.DETAILED DESCRIPTION

[0028] Provided herein are methods for the treatment, analysis, characterization, and diagnosis of a disease or condition, e.g., an inflammatory disease such as IBD (e.g., Crohn’s disease (CD) or ulcerative colitis (UC)). Also provided are methods of selection for treatment of a disease or condition, e.g., an inflammatory disease such as IBD (e.g., CD or UC). In certain aspects, described herein is a method of treating a disease or condition in a subject, e.g., an inflammatory disease such as IBD (e.g., CD or UC).Certain Definitions

[0029] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

[0030] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0031] As used in the specification and claims, the singular forms “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.

[0032] Reference throughout this specification to “some embodiments,” “further embodiments,” or “a particular embodiment,” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrase “in some embodiments,” or “in further embodiments,” or “in a particular embodiment” in variousplaces throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0033] As used herein the term “control” or “reference” may generally refer to a sample, level, amount, or group that can be used for purposes of comparison. In some examples, a “control” or “reference” may refer to a sample, level, amount, or group in a scientific experiment in which the independent variable cannot influence the outcome.

[0034] The terms “determining,” “measuring,” and “analyzing” are often used interchangeably herein to refer to forms of measurement. The terms include determining if an element (e.g., a marker such as a serological marker or a genotype) is present or not (for example, detection). These terms can include quantitative, qualitative, or quantitative and qualitative determinations. Determining can be relative or absolute. “Detecting the presence of’ can include determining the amount of something present in addition to determining whether it is present or absent depending on the context.

[0035] The term “in vivo " is used to describe an event that takes place in a subject’s body.

[0036] The term in vitro is used to describe an event that takes places contained in a container for holding laboratory reagent such that it is separated from the biological source from which the material is obtained. In vitro assays can encompass cell-based assays in which living or dead cells are employed. In vitro assays can also encompass a cell-free assay in which no intact cells are employed.

[0037] As used herein, the term “about” a number refers to that number plus or minus 10% of that number. The term “about” with reference to a range refers to that range minus 10% of its lowest value and plus 10% of its greatest value.

[0038] The terms “increased” or “increase” are used herein to generally mean an increase by a statistically significant amount. In some embodiments, the terms “increased” or “increase” mean an increase of at least 10% as compared to a reference level, for example an increase of at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100% as compared to a reference level, standard, or control. Other examples of “increase” include an increase of at least 2-fold, at least 5-fold, at least 10-fold, at least 20- fold, at least 50-fold, at least 100-fold, at least 1000-fold or more as compared to a reference level. An increase can be an absolute amount (e.g., level of protein expression), or a rate of production (e.g., rate of protein expression between two points in time).

[0039] The terms “decreased” or “decrease” are used herein generally to mean a decrease by a statistically significant amount. In some embodiments, “decreased” or “decrease” means a reduction by at least 10% as compared to a reference level, for example a decrease of at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% decrease (e.g., absent level or non-detectable level as compared to a reference level), or any decrease between 10-100%as compared to a reference level. Other examples of “decrease” include a decrease of at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 1000-fold or more as compared to a reference level. A decrease can be an absolute amount (e.g., level of protein expression), or a rate of production (e.g., rate of protein expression between two points in time). In the context of a marker or symptom, by these terms is meant a statistically significant decrease in such level.

[0040] The term “subject” encompasses mammals. Non-limiting examples of mammal include any member of the mammalian class, including: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. In one aspect, the mammal is a human. The term “animal” as used herein comprises human beings and non-human animals. In one embodiment, a “non-human animal” is a mammal, for example a rodent such as rat or a mouse. In some embodiments, a human subject is a “patient,” which as used herein, refers to a subject who has or may be diagnosed with a disease or condition disclosed herein (e.g., an inflammatory disease such as IBD (e.g., CD or UC).

[0041] The term “gene,” as used herein, refers to a segment of nucleic acid that encodes an individual protein or RNA (also referred to as a “coding sequence” or “coding region”), optionally together with associated regulatory region such as promoter, operator, terminator and the like, which may be located upstream or downstream of the coding sequence. A “genetic locus” referred to herein, is a particular location within a gene.

[0042] The term “genotype” as disclosed herein, refers to the chemical composition of a polynucleotide sequence within the genome of an individual. In some embodiments, the genotype comprises a polymorphism such as a single nucleotide polymorphism (SNP) or an indel (insertion or deletion, of a nucleobase within a polynucleotide sequence). In some embodiments, a genotype for a particular SNP or indel is heterozygous. In some embodiments, a genotype for a particular SNP or indel is homozygous.

[0043] A “polymorphism” as used herein refers to an aberration in (e.g., a mutation), or of (e.g., insertion / deletion), a nucleic acid sequence, as compared to the nucleic acid sequence in a reference population. In some embodiments, the polymorphism is common in the reference population. In some embodiments, the polymorphism is rare in the reference population. In some embodiments, the polymorphism is a SNP.

[0044] The term “single nucleotide polymorphism” or SNP as disclosed herein, refers to a variation in a single nucleotide within a polynucleotide sequence. The term should not be interpreted as placing a restriction on a frequency of the SNP in a given population. The variation of an SNP may have multiple different forms. A single form of an SNP is referred to as an “allele.” An SNP can be mono-, bi-, tri, or tetra-allelic. A SNP may include a “risk allele,” a “protective allele,” or neither. By way of example, a reference polynucleotide sequence reading 5 ’ to 3 ’ is TTACG. A SNP at allele position 3 (of 5 ’ -TTACG- 3’) comprise a substitution of the reference allele, “A” to a non-reference allele, “C.” If the “C” allele of the SNP is associated with an increased probability of developing a phenotypic trait (e.g., a thiopurine-induced adverse event), the allele is considered a “risk” allele. However, the same SNP may also comprise a substitution of the “A” allele to a “T” allele at position 3. If the T allele of the SNP is associated with a decreased probability of developing a phenotypic trait, the allele is considered a “protective” allele. The SNP may be observed in at least 1% of a given population. In some embodiments, the SNP is represented by an “rs” number, which refers to the accession of reference cluster of one more submitted SNPs in the dbSNP bioinformatics database as of the fding date of this patent application, and which is included within a sequence that comprises the total number of nucleobases from 5 ’ to 3 ’ . In some embodiments, a SNP may be further defined by the position of the SNP (nucleobase) within the dbSNP sequence, the position of which is always with reference to 5’ length of the sequence plus 1. In some embodiments, a SNP is defined as the genomic position in a reference genome and the allele change (e.g., chromosome 7 at position 234,123,567 from G allele to A allele in the reference human genome build 37). In some embodiments, the SNP is defined as the genomic position identified with [brackets] or an “N” in a sequence disclosed herein.

[0045] The term “indel” as disclosed herein refers to an insertion, or a deletion, of a nucleobase within a polynucleotide sequence. An indel can be mono-, bi-, tri, or tetra-allelic. An indel may be “risk,” “protective,” or neither, for a phenotypic trait. In some embodiments, the indel is represented by an “rs” number, which refers to the accession of reference cluster of one more submitted indels in the dbSNP bioinformatics database as of the filing date of this patent application, and which is included in a sequence that comprises the total number of nucleobases from 5’ to 3’. In some embodiments, an indel may be further defined by the position of the insertion / deletion within the dbSNP sequence, the position of which is always with reference to the 5 ’ length of the sequence plus 1. In some embodiments, an indel is defined as the genomic position in a reference genome and the allele change. In some embodiments, the indel is defined as the genomic position identified with [brackets] or an “N” in a sequence disclosed herein.

[0046] “Haplotype” as used herein, encompasses a group of one or more genotypes, which tend to be inherited together in a reference population. In some embodiments, a haplotype comprises a particular polymorphism or another polymorphism in linkage disequilibrium (LD) therewith.

[0047] “Linkage disequilibrium,” or “LD,” as used herein refers to the non-random association of alleles or indels in different gene loci in a given population. LD may be defined by a D’ value corresponding to the difference between an observed and expected allele or indel frequencies in the population (D=Pab- PaPb), which is scaled by the theoretical maximum value of D. LD may be defined by an r2 value corresponding to the difference between an observed and expected unit of risk frequencies in the population (D=Pab-PaPb), which is scaled by the individual frequencies of the different loci. In some embodiments, D’ comprises at least 0.20. In some embodiments, r2 comprises at least 0.70.

[0048] The term “medically refractory,” or “refractory,” as used herein, refers to the failure of a standard treatment to induce remission of a disease. In some embodiments, the disease comprises an inflammatory disease disclosed herein (e.g., IBD, including CD or UC). A non-limiting example of refractory inflammatory disease includes refractory Crohn’s disease, and refractory ulcerative colitis (e.g., mrUC).Non-limiting examples of standard treatment include glucocorticosteroids, anti-TNF therapy, anti-a4-b7 therapy (e.g., vedolizumab), anti-IL12p40 therapy (e.g., ustekinumab), thalidomide, and cyclophosphamide .

[0049] The terms “treat,” “treating,” and “treatment” as used herein refer to alleviating or abrogating a disorder, disease, or condition (e.g., IBD, including CD or UC); or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating a cause of the disorder, disease, or condition itself. Desirable effects of treatment can include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishing any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state and remission or improved prognosis.

[0050] The term “therapeutically effective amount” refers to the amount of a compound or therapy that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of a disorder, disease, or condition of the disease; or the amount of a compound that is sufficient to elicit biological or medical response of a cell, tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor, or clinician.

[0051] The term “thiopurine” as used herein refers to a class of purine antimetabolite drugs. Thiopurine drugs may be used in treatment of inflammatory and autoimmune disorders such as Crohn’s disease and rheumatoid arthritis, cancers such as acute lymphoblastic leukemia, and for organ transplant recipients. In some examples, metabolism of thiopurine drugs is catalyzed by nudix hydrolase 15 (NUDT15) and / or S- methyltransferase. Exemplary thiopurine drugs include, but are not limited, to mercaptopurine (e.g., 6- mercaptopurine, 6-MP), thioguanine (e.g., 6-thioguanine, 6-TG), and azathioprine (AZA). Thiopurine drugs are also described, e.g., in Warner et al. Front. Gastroenterol. 9(1): 10-15, 2018; Tominaga et al. Front. Pharmacol. 11:582291, 2020; and Singh et al. Intest. Res. 20(1): 11-30, 2022.

[0052] The term “thiopurine-induced adverse event” refers to an adverse event that is induced by or associated with treatment with one or more thiopurine drugs. In some examples, the thiopurine -induced adverse event comprises one or more of bone marrow (BM) toxicity, leukopenia, pancreatitis, hepatotoxicity, gastrointestinal (GI) intolerance, arthralgia, rash, high fever, and hypersensitivity.

[0053] The term “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” “physiologically acceptable carrier,” or “physiologically acceptable excipient” refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid fdler, diluent, excipient, solvent, or encapsulating material. A component can be “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation. It can also be suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0054] The term “pharmaceutical composition” refers to a mixture of a compound disclosed herein with other chemical components, such as diluents or carriers. The pharmaceutical composition can facilitateadministration of the compound to an organism (e.g., a subject or patient as disclosed herein). Multiple techniques of administering a compound exist in the art including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.

[0055] The term “inflammatory bowel disease” or “IBD” as used herein refers to gastrointestinal disorders of the gastrointestinal tract. Non-limiting examples of IBD include, Crohn’s disease (CD), ulcerative colitis (UC), indeterminate colitis (IC), microscopic colitis, diversion colitis, Behcet’s disease, and other inconclusive forms of IBD. In some embodiments, IBD comprises fibrosis, fibrostenosis, stricturing and / or penetrating disease, obstructive disease, or a disease that is refractory (e.g., mrUC, refractory CD), perianal CD, or other complicated forms of IBD.

[0056] Non-limiting examples of “sample” include any material from which an analyte, including nucleic acids (e.g., DNA or RNA) and / or proteins, can be obtained. As non-limiting examples, this includes whole blood, peripheral blood, plasma, serum, saliva, mucus, urine, semen, lymph, fecal extract, cheek swab, cells or other bodily fluid or tissue, including but not limited to tissue obtained through surgical biopsy or surgical resection. In various embodiments, the sample comprises tissue from the large and / or small intestine. In various embodiments, the large intestine sample comprises the cecum, colon (the ascending colon, the transverse colon, the descending colon, and the sigmoid colon), rectum and / or the anal canal. In some embodiments, the small intestine sample comprises the duodenum jejunum, and / or the ileum. Alternatively, a sample can be obtained through primary patient derived cell lines, or archived patient samples in the form of preserved samples, or fresh frozen samples. A sample may comprise blood, serum, plasma, sweat, hair, tears, urine, saliva, stool, or combination thereof.

[0057] The terms “marker” and “biomarker” refer to a measurable substance in a subject whose presence, level, or activity, is indicative of a phenomenon (e.g., phenotypic expression or activity; disease, condition, subclinical phenotype of a disease or condition, infection; or environmental stimuli). In some embodiments, a biomarker comprises a gene, gene expression product (e.g., RNA or protein), or a celltype (e.g., immune cell).

[0058] The term “serological marker,” as used herein refers to a type of biomarker representing an antigenic response in a subject that may be detected in the serum of the subject. In some embodiments, a serological comprises an antibody against various fungal antigens. Non-limiting examples of a serological marker comprise an anti -neutrophil cytoplasmic antibody (ANCA), anti-12 antibody, anti-Saccharomyces cerevisiae antibody (ASCA), E.coli outer membrane porin protein C (OmpC), anti-Malassezia restricta antibody, anti-Malassezia pachydermatis antibody, anti-Malassezia furfur antibody, anti-Malassezia globasa antibody, anti-Cladosporium albicans antibody, anti-laminaribiose antibody (ALCA), anti- chitobioside antibody (ACCA), anti-laminarin antibody, anti-chitin antibody, pANCA antibody, and anti- Cbirl flagellin antibody.

[0059] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.Therapeutic Methods and Uses

[0060] Provided herein are methods, uses, and compositions for use in treating a disease or condition, e.g., an inflammatory disease such as IBD (e.g., CD or UC). Although IBD is used as an example in the discussion below, it is to be understood that the methods disclosed herein may be used for other diseases or conditions, including those that are treated with thiopurine drugs, including inflammatory and autoimmune disorders such as rheumatoid arthritis, cancers such as acute lymphoblastic leukemia, and for organ transplant recipients.

[0061] In one aspect, provided herein is a method of treating a disease or condition in a subject, the method comprising: administering to the subject a therapeutically effective amount of a thiopurine drug, wherein the subject: (a) does not comprise a serological marker comprising antinuclear cytoplasmic antibody (ANCA), antipseudomonas fluorescens-related protein (i2), or any combination thereof; (b) does not comprise a genotype comprising aNUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) does not comprise a genotype comprising HLA- DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (d) any combination thereof. In some embodiments, the disease or condition is an inflammatory disorder (e.g., IBD, including CD or UC), an autoimmune disorder (e.g., rheumatoid arthritis), a cancer (e.g., acute lymphoblastic leukemia), or an organ transplant.

[0062] In one aspect, provided herein is a method of treating an IBD in a subject, the method comprising: administering to the subject a therapeutically effective amount of a thiopurine drug for the treatment of IBD, wherein the subject: (a) does not comprise a serological marker comprising antinuclear cytoplasmic antibody (ANCA), antipseudomonas fluorescens-related protein (i2), or any combination thereof; (b) does not comprise a genotype comprising aNUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) does not comprise a genotype comprising HLA- DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (d) any combination thereof.

[0063] In another aspect, provided herein is a method of treating an IBD in a subject, the method comprising: (a) determining that the subject: (i) does not comprise a serological marker comprising antinuclear cytoplasmic antibody (ANCA), antipseudomonas fluorescens-related protein (i2), or any combination thereof; (ii) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (iii) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iv) any combination thereof; and (b) administering to the subject a therapeutically effective amount of a thiopurine drug.

[0064] In another aspect, provided herein is method of treating an IBD in a subject, the method comprising administering a therapeutically effective amount of a therapeutic agent for the treatment of IBD other than a thiopurine drug to the subject, wherein the subject comprises: (a) a serological marker comprising ANCA, i2, or any combination thereof; (b) a genotype comprising aNUDT15 variantcomprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (d) any combination thereof.

[0065] In another aspect, provided herein is a thiopurine drug for use in treating an IBD in a subject, wherein the subject: (a) does not comprise a serological marker comprising ANCA, i2, or any combination thereof; (b) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (d) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or I any combination thereof.

[0066] In another aspect, provided herein is a thiopurine drug for use in a method of treating an IBD in a subject, the method comprising: (a) determining that the subject: (i) does not comprise a serological marker comprising antinuclear cytoplasmic antibody (ANCA), antipseudomonas fluorescens-related protein (i2), or any combination thereof; (ii) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (I3:48037782:AGGAGTC:A, rs74607I566); (iii) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-I2*02, or any combination thereof; or (iv) any combination thereof; and (b) administering to the subject a thiopurine drug.

[0067] In another aspect, provided herein is a therapeutic agent for the treatment of IBD other than a thiopurine drug for use in treating an IBD in a subject, wherein the subject comprises: (a) a serological marker comprising ANCA, i2, or any combination thereof; (b) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (d) any combination thereof.

[0068] In another aspect, provided herein is the use of a thiopurine drug in the manufacture of a medicament for treating an IBD in a subject, wherein the subject: (a) does not comprise a serological marker comprising ANCA, i2, or any combination thereof; (b) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-I2*02, or any combination thereof; or (d) any combination thereof.

[0069] In another aspect, provided herein is the use of a thiopurine drug in the manufacture of a medicament for use in a method of treating an IBD in a subject, the method comprising: (a) determining that the subject: (i) does not comprise a serological marker comprising antinuclear cytoplasmic antibody (ANCA), antipseudomonas fluorescens-related protein (i2), or any combination thereof; (ii) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (I3:48037782:AGGAGTC:A, rs74607I566); (iii) does not comprise a genotype comprising HLA- DQAI*2, HLA-DRB1*7, HLADPB1* 17, HLAC-I2*02, or any combination thereof; or (iv) any combination thereof; and (b) administering to the subject a thiopurine drug.

[0070] In another aspect, provided herein is the use of a therapeutic agent for the treatment of IBD other than a thiopurine drug in the manufacture of a medicament for treating an IBD in a subject, wherein the subject comprises: (a) a serological marker comprising ANCA, i2, or any combination thereof; (b) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (c) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (d) any combination thereof.

[0071] In some embodiments, the presence of the serological marker or the genotype is detected in a sample obtained from the subject. Any suitable sample may be used, including any sample disclosed herein. In some embodiments, the sample comprises blood, serum, plasma, sweat, hair, tears, urine, saliva, stool, or a combination thereof. In some embodiments, the sample comprises serum.

[0072] In some embodiments, the serological marker is detected by a method comprising an enzyme - linked immunosorbent assay (ELISA). In some embodiments, the method further comprises seropositivity or seronegativity of the serological marker. In some embodiments, the measuring the seropositivity or the seronegativity comprises calculating a percentage of a reference value from pooled sera obtained from a patient population diagnosed with IBD.

[0073] In some embodiments, the genotype is detected by a method comprising detecting a nucleic acid sequence. Any suitable approach may be used. In some embodiments, the detecting the nucleic acid sequence comprises performing quantitative polymerase chain reaction (qPCR), nucleic acid sequencing, or hybridization to immobilized nucleic acid sequences on a nucleic acid array.

[0074] Any suitable thiopurine drug or combination thereof may be used. Exemplary thiopurine drugs include, but are not limited, to mercaptopurine (e.g., 6-mercaptopurine, 6-MP), thioguanine (e.g., 6- thioguanine, 6-TG), and azathioprine (AZA). In some embodiments, the thiopurine drug includes azathioprine and 6-mercaptopurine.

[0075] In some embodiments, the therapeutic agent for the treatment of IBD other than a thiopurine drug comprises a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of tumor necrosis factor alpha (TNFa), an inhibitor of interleukin-23 (IL23), an inhibitor of integrin, an inhibitor of Sphingosine- 1 - phosphate receptor (S1PR), an inhibitor of TNF superfamily member 15 (TL1A), an inhibitor of CD30 ligand (CD30L), an inhibitor of Janus kinase 2 (JAK), an antagonist of interleukin -21 (IL21), or any combination thereof.

[0076] In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject. In some embodiments, the one or more additional therapeutic agents comprise a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of TNFa, an inhibitor of IL23, an inhibitor of integrin, an inhibitor of S1PR, an inhibitor of TL1A, an inhibitor of CD30L, an inhibitor of JAK, an antagonist of IL21, or any combination thereof.

[0077] In some embodiments, the inhibitor of tumor necrosis factor alpha (TNFa) comprises adalimumab, infliximab, golimumab, certolizumab, or etanercept, or any combination thereof.

[0078] In some embodiments, the inhibitor of IL23 comprises ustekinumab, guselkumab, risankizumab, brazikumab, mirikizumab, tildrakizumab, or briakinumab, or any combination thereof.

[0079] In some embodiments, the inhibitor of integrin comprises etrolizumab, vedolizumab, natalizumab, or ontamalimab, or any combination thereof.

[0080] In some embodiments, the inhibitor of S 1PR comprises fmgolimod, siponimod, etrasimod, ozanimod, ponesimod, amiselimod, ceralifimod, or mocravimod, or any combination thereof.

[0081] In some embodiments, the inhibitor of TL1A comprises tulisokibart, RVT-3101 / PF-06480605, or duvakitug, or any combination thereof.

[0082] In some embodiments, the antagonist of IL21 comprises an antibody or an antigen -binding fragment thereof.

[0083] In some embodiments, the thiopurine drug comprises azathioprine, mercaptopurine, or thioguanine. In some embodiments, a combination of thiopurine drugs is administered to the subject, e.g., AZA and 6-MP.

[0084] In some embodiments, the thiopurine-induced adverse event comprises one or more of bone marrow (BM) toxicity, leukopenia, pancreatitis, hepatotoxicity, gastrointestinal (GI) intolerance, arthralgia, rash, high fever, and hypersensitivity.Methods of Determining the Likelihood of Thiopurine-induced Adverse Events

[0085] Also provided herein are methods of determining whether a subject having a disease or condition, e.g., an inflammatory disease such as IBD (e.g., CD or UC), is likely to experience a thiopurine-induced adverse event. In some embodiments, the methods may be used for patient identification, selection, or stratification. Although IBD is used as an example in the discussion below, it is to be understood that the methods disclosed herein may be used for other diseases or conditions, including those that are treated with thiopurine drugs, including inflammatory and autoimmune disorders such as rheumatoid arthritis, cancers such as acute lymphoblastic leukemia, and for organ transplant recipients.

[0086] For example, in one aspect, provided herein is a method of determining whether a subject is likely to experience a thiopurine-induced adverse event, the method comprising: (a) detecting the presence of one or more of the following in the subject: (i) a serological marker comprising ANCA, i2, or any combination thereof; (ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iv) any combination thereof; and (b) determining a likelihood that the subject will experience a thiopurine -induced adverse event based, at least in part, on the presence of one or more of (i) - (iv) detected in the subject, wherein the likelihood is compared with a control subject. In some embodiments, the method further comprises selecting a therapeutic agent for the treatment of a disease or condition other than a thiopurine drug for the subject. In some embodiments, the method further comprises administering a therapeutic agent other than a thiopurine drug to the subject.

[0087] In another example, in one aspect, provided herein is a method of determining whether a subject having IBD is likely to experience a thiopurine -induced adverse event, the method comprising: (a) detecting the presence of one or more of the following in the subject: (i) a serological marker comprising ANCA, i2, or any combination thereof; (ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (iii) a genotype comprising HLA- DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iv) any combination thereof; and (b) determining a likelihood that the subject will experience a thiopurine- induced adverse event based, at least in part, on the presence of one or more of (i) - (iv) detected in the subject, wherein the likelihood is compared with a control subject having IBD. In some embodiments, the method further comprises selecting a therapeutic agent for the treatment of IBD other than a thiopurine drug for the subject. In some embodiments, the method further comprises administering a therapeutic agent for the treatment of IBD other than a thiopurine drug to the subject.

[0088] In another aspect, provided herein is a method of selecting a therapy for a subject having IBD, the method comprising: (a) detecting the presence or absence of one or more of the following in the subject: (i) a serological marker comprising ANCA, i2, or any combination thereof; (ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-I2*02, or any combination thereof; or (iv) any combination thereof; (b) determining a likelihood that the subject will experience a thiopurine -induced adverse event based, at least in part, on the presence or absence of one or more of (i) - (iv) detected in the subject, wherein the likelihood is compared with a control subject having IBD; and (c) selecting a thiopurine drug for the subject if the subject does not have a likelihood of having a thiopurine- induced adverse event or selecting a therapeutic agent for treatment of IBD other than a thiopurine drug if the subject has a likelihood of having a thiopurine-induced adverse event. In some embodiments, the subject has a likelihood of having a thiopurine -induced adverse event, and the method further comprises administering a therapeutic agent for the treatment of IBD other than a thiopurine drug to the subject. In other embodiments, the subject does not have a likelihood of having a thiopurine -induced adverse event, and the method further comprises administering a thiopurine drug to the subject.

[0089] In some embodiments, the presence of the serological marker or the genotype is detected in a sample obtained from the subject. Any suitable sample may be used, including any sample disclosed herein. In some embodiments, the sample comprises blood, serum, plasma, sweat, hair, tears, urine, saliva, stool, or a combination thereof. In some embodiments, the sample comprises serum.

[0090] In some embodiments, the serological marker is detected by a method comprising an ELISA. In some embodiments, the method further comprises seropositivity or seronegativity of the serological marker. In some embodiments, the measuring the seropositivity or the seronegativity comprises calculating a percentage of a reference value from pooled sera obtained from a patient population diagnosed with IBD.

[0091] In some embodiments, the genotype is detected by a method comprising detecting a nucleic acid sequence. Any suitable approach may be used. In some embodiments, the detecting the nucleic acid sequence comprises performing qPCR, nucleic acid sequencing, or hybridization to immobilized nucleic acid sequences on a nucleic acid array.

[0092] In some embodiments, the therapeutic agent for the treatment of IBD other than a thiopurine drug comprises a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of TNFa, an inhibitor of IL23, an inhibitor of integrin, an inhibitor of SI PR, an inhibitor of TL1A, an inhibitor of CD30L, an inhibitor of JAK, an antagonist of IL21, or any combination thereof.

[0093] In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject. In some embodiments, the one or more additional therapeutic agents comprise a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of TNFa, an inhibitor of IL23, an inhibitor of integrin, an inhibitor of S1PR, an inhibitor of TL1A, an inhibitor of CD30L, an inhibitor of JAK, an antagonist of IL21, or any combination thereof.

[0094] In some embodiments, the inhibitor of tumor necrosis factor alpha (TNFa) comprises adalimumab, infliximab, golimumab, certolizumab, or etanercept, or any combination thereof.

[0095] In some embodiments, the inhibitor of IL23 comprises ustekinumab, guselkumab, risankizumab, brazikumab, mirikizumab, tildrakizumab, or briakinumab, or any combination thereof.

[0096] In some embodiments, the inhibitor of integrin comprises etrolizumab, vedolizumab, natalizumab, or ontamalimab, or any combination thereof.

[0097] In some embodiments, the inhibitor of S 1PR comprises fmgolimod, siponimod, etrasimod, ozanimod, ponesimod, amiselimod, ceralifimod, or mocravimod, or any combination thereof.

[0098] In some embodiments, the inhibitor of TL1A comprises tulisokibart, RVT-3101 / PF-06480605, or duvakitug, or any combination thereof.

[0099] In some embodiments, the antagonist of IL21 comprises an antibody or an antigen-binding fragment thereof.

[0100] In some embodiments, the thiopurine drug comprises azathioprine, mercaptopurine, or thioguanine. In other examples, a combination of thiopurine drugs is used, e.g., azathioprine and mercaptopurine.

[0101] In some embodiments, the thiopurine-induced adverse event comprises one or more of BM toxicity, leukopenia, pancreatitis, hepatotoxicity, GI intolerance, arthralgia, rash, high fever, and hypersensitivity.

[0102] In some embodiments, the therapeutic agent is administered in a therapeutically effective amount.Serological Factors

[0103] In some embodiments, the methods, uses, compositions, systems, or kits disclosed herein involve detection of one or more serological factors. Any suitable serological factors may be detected. In some embodiments, the one or more serological factors comprises one or more selected from the group consisting of ANCA, i2, or a combination thereof.

[0104] In some embodiments, seropositivity or seronegativity is measured by calculating a percentage of a reference value from pooled sera obtained from a patient population diagnosed with IBD.

[0105] In some embodiments, the methods comprise identifying the subject as having a high likelihood of an adverse event from treatment with a thiopurine drug if the subject exhibits ANCA seropositivity. In some embodiments, the methods comprise identifying the subject as having a high likelihood of an adverse event from treatment with a thiopurine drug if the subject exhibits i2 seropositivity. In some embodiments, the methods comprise identifying the subject as having a high likelihood of an adverse event from treatment with a thiopurine drug if the subject exhibits ANCA seropositivity and i2 seropositivity.Genetic Factors

[0106] Disclosed herein are genotypes related to risk of an adverse event from treatment with a thiopurine drug in a subject with IBD. In some embodiments, the methods, uses, compositions, systems or kits disclosed herein may involve detection of one or more genetic factors related to a risk of an adverse event from treatment with a thiopurine drug, including a genotype comprising aNUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); a genotype comprising HLA- DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or any combination thereof.

[0107] Any suitable approach may be used to detect a genotype as disclosed herein. In some embodiments, the genotypes that may be detected in a sample obtained from a subject by analyzing the genetic material in the sample. In some embodiments, the subject may be human. In some embodiments, the genetic material is obtained from a subject having a disease or condition disclosed herein, e.g., an inflammatory disease such as IBD. The sample may be derived from any suitable biological fluid or tissue containing genetic material. In some cases, the genetic material is obtained from blood, serum, plasma, sweat, hair, tears, urine, buccal swab, or any other suitable sample. In some embodiments, the genetic material is obtained from a biopsy, e.g., from the intestinal tract of the subject.

[0108] The genotypes described herein may be detected using suitable genotyping devices (e.g., array or sequencing). In some embodiments, a sample is obtained from the subject or patient indirectly or directly. In some embodiments, the sample may be obtained by the subject. In other instances, the sample may be obtained by a healthcare professional, such as a nurse or physician.

[0109] The genotypes of the present disclosure comprise genetic material that is deoxyribonucleic acid (DNA). In some embodiments, the genotype comprises a denatured DNA molecule or fragment thereof. In some embodiments, the genotype comprises DNA selected from: genomic DNA, viral DNA, mitochondrial DNA, plasmid DNA, amplified DNA, circular DNA, circulating DNA, cell-free DNA, or exosomal DNA. In some embodiments, the DNA is single -stranded DNA (ssDNA), double -stranded DNA, denaturing double -stranded DNA, synthetic DNA, and combinations thereof. The circular DNA may be cleaved or fragmented.

[0110] The genotypes disclosed herein comprise at least one polymorphism located at a gene or genetic locus described herein. In some embodiments, the gene or genetic locus is NUDT15. The genotypes disclosed herein are, in some cases, a haplotype. In some embodiments, the genotype comprises a particular polymorphism, a polymorphism in linkage disequilibrium (LD) therewith, or a combination thereof. In some cases, LD is defined by an r2of at least or about 0.70, 0.75, 0.80, 0.85, 0.90, or 1.0. The genotypes disclosed herein can comprise at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more polymorphisms.

[0111] The polymorphisms described herein can be a single nucleotide polymorphism, or an indel (insertion / deletion). In some embodiments, the polymorphism is an insertion or a deletion of at least one nucleobase (e.g., an indel). In some embodiments, the genotype may comprise a copy number variation (CNV), which is a variation in a number of a nucleic acid sequence between individuals in a given population. In some embodiments, the CNV comprises at least or about two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, forty or fifty nucleic acid molecules. In some embodiments, the genotype is heterozygous. In some embodiments, the genotype is homozygous.

[0112] In some embodiments, the methods, uses, compositions, systems, or kits may involve detection or imputation of HLA genes, including, without limitation, HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof.Subject

[0113] The subject disclosed herein can be a mammal, such as for example a mouse, rat, guinea pig, rabbit, non-human primate, or farm animal. In preferred embodiments, the subject is human. In some embodiments, the subject is suffering from a symptom related to a disease or condition disclosed herein (e.g., abdominal pain, cramping, diarrhea, rectal bleeding, fever, weight loss, fatigue, loss of appetite, dehydration, and malnutrition, anemia, or ulcers). In some embodiments, the subject is a pediatric subject. For instance, a human subject may be 17 years old or younger. In some embodiments, the subject is an adult subject. For instance, a human subject may be between 18 and 64 years old. In some embodiments, the subject is an elderly subject. For instance, a human subject may be 65 years old or older. In some embodiments, the subject is female. In some embodiments, the subject is male.

[0114] In some embodiments, the subject is susceptible to, or is inflicted with, thiopurine toxicity, or a disease caused by thiopurine toxicity (such as pancreatitis or leukopenia). The subject may experience, or may be suspected of experiencing, non-response or loss-of-response to a standard treatment (e.g., antitumor necrosis factor (TNF) therapy, anti-a4-b7 therapy (e.g., vedolizumab), anti-IL12p40 therapy (e.g., ustekinumab), thalidomide, a glucocorticosteroid, or cyclophosphamide). In some embodiments, the subject may be currently receiving one or more of the standard therapies disclosed herein as a “first-line” therapy, such as the anti-TNF therapy and a glucocorticosteroid. In some embodiments, the subject is in need of a “second-line” therapy because the subject is either not responding to an induction of the standard therapy or has lost response to the standard therapy during a treatment course or regimen.Disease or Condition

[0115] The methods, compositions, uses, systems, and kits disclosed herein may be used for patient identification, selection, stratification, or treatment of any suitable disease or condition. In some embodiments, the disease or the condition is an inflammatory disease, a fibrotic disease, or a fibrostenotic disease. In some embodiments, the disease is an IBD, such as Crohn’s disease (CD) or ulcerative colitis (UC). In some embodiments, the Crohn’s disease is moderate to severe Crohn’s disease. In some cases, the CD is severe CD. The severe CD may result from inflammation that has led to the formation of scar tissue in the intestinal wall (fibrostenosis) and / or swelling. In some cases, the severe CD is characterized by the presence of fibrotic and / or inflammatory strictures. The strictures may be determined by computed tomography enterography (CTE), and magnetic resonance imaging enterography (MRE). The disease or condition may be characterized as refractory, which in some cases, means the disease is resistant to a standard treatment (e.g., anti-TNFa therapy). Non-limiting examples of standard treatment include glucocorticosteroids, anti-TNF therapy, anti-a4-b7 therapy (e.g., vedolizumab), anti-IL12p40 therapy (e.g., ustekinumab), thalidomide, and cyclophosphamide.

[0116] In other examples, the disease or condition is one that may be treated with a thiopurine drug, including inflammatory and autoimmune disorders such as rheumatoid arthritis, cancers such as acute lymphoblastic leukemia, and for organ transplant recipients.Methods of detecting a genotype

[0117] The methods, compositions, uses, systems, and kits disclosed herein for detecting a genotype in a sample from a subject may comprise analyzing the genetic material in the sample to detect at least one of a presence, an absence, and a quantity of a nucleic acid sequence encompassing the genotype of interest. In some embodiments, the genotype of interest is a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); a genotype comprising HLA- DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or any combination thereof.

[0118] In some cases, the nucleic acid sequence comprises DNA. In some embodiments, the nucleic acid sequence comprises a denatured DNA molecule or fragment thereof. In some embodiments, the nucleic acid sequence comprises DNA selected from: genomic DNA, viral DNA, mitochondrial DNA, plasmid DNA, amplified DNA, circular DNA, circulating DNA, cell-free DNA, complementary DNA (cDNA), or exosomal DNA. In some embodiments, the DNA is single -stranded DNA (ssDNA), double -stranded DNA, denaturing double -stranded DNA, synthetic DNA, and combinations thereof. The circular DNA may be cleaved or fragmented. In some embodiments, the nucleic acid sequence comprises RNA. In some embodiments, the nucleic acid sequence comprises fragmented RNA. In some embodiments, the nucleic acid sequence comprises partially degraded RNA. In some embodiments, the nucleic acid sequence comprises a microRNA or portion thereof. In some embodiments, the nucleic acid sequence comprises anRNA molecule or a fragmented RNA molecule (RNA fragments) selected from: a microRNA (miRNA), a pre-miRNA, a pri-miRNA, a mRNA, a pre-mRNA, a viral RNA, a viroid RNA, a virusoid RNA, circular RNA (circRNA), a ribosomal RNA (rRNA), a transfer RNA (tRNA), a pre-tRNA, a long non-coding RNA (IncRNA), a small nuclear RNA (snRNA), a circulating RNA, a cell-free RNA, an exosomal RNA, a vector-expressed RNA, an RNA transcript, a synthetic RNA, and combinations thereof.

[0119] Nucleic acid-based detection techniques that may be useful for the methods herein include quantitative polymerase chain reaction (qPCR), gel electrophoresis, immunochemistry, in situ hybridization such as fluorescent in situ hybridization (FISH), cytochemistry, and next generation sequencing. In some embodiments, the methods involve TaqMan™ qPCR, which involves a nucleic acid amplification reaction with a specific primer pair, and hybridization of the amplified nucleic acids with a hydrolysable probe specific to a target nucleic acid.

[0120] In some embodiments, the methods involve hybridization and / or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses, and probe arrays. Non-limiting amplification reactions include, but are not limited to, qPCR, self-sustained sequence replication, transcriptional amplification system, Q-Beta Replicase, rolling circle replication, or any other nucleic acid amplification. As discussed, reference to qPCR herein includes use of TaqMan™ methods. An additional hybridization assay includes the use of nucleic acid probes conjugated or otherwise immobilized on a bead, multi-well plate, or other substrate, wherein the nucleic acid probes are configured to hybridize with a target nucleic acid sequence of a genotype provided herein.

[0121] In some embodiments, detecting the presence or absence of a genotype comprises sequencing genetic material from the subject. Sequencing can be performed with any appropriate sequencing technology, including but not limited to single-molecule real-time (SMRT) sequencing, polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam -Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis. Sequencing methods also include next-generation sequencing (NGS), e.g., modem sequencing technologies such as Illumina® sequencing (e.g., Illumina® sequencing-by-synthesis), Roche 454 sequencing, Ion Torrent™ sequencing, and SOLiD® (Sequencing by Oligonucleotide Ligation and Detection) sequencing. In some cases, next-generation sequencing involves high-throughput sequencing methods. Additional sequencing methods may also be employed.

[0122] In some embodiments, sequencing the nucleic acid in the sample comprises preparing a sample library for sequencing. In some embodiments, preparing the sample library for sequencing comprises one or more, or all, of the following: sample dilution, cell lysis, tagmentation, tagmentation cleanup, nucleic acid amplification, immobilization, fragmentation, ligation, end repair, barcoding, and combinations hereof.

[0123] In some embodiments, a number of nucleotides that are sequenced are at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 400, 500, 2000, 4000, 6000, 8000, 10000, 20000, 50000, 100000,or more than 100000 nucleotides. In some embodiments, the number of nucleotides sequenced is in a range of about 1 to about 100000 nucleotides, about 1 to about 10000 nucleotides, about 1 to about 1000 nucleotides, about 1 to about 500 nucleotides, about 1 to about 300 nucleotides, about 1 to about 200 nucleotides, about 1 to about 100 nucleotides, about 5 to about 100000 nucleotides, about 5 to about 10000 nucleotides, about 5 to about 1000 nucleotides, about 5 to about 500 nucleotides, about 5 to about 300 nucleotides, about 5 to about 200 nucleotides, about 5 to about 100 nucleotides, about 10 to about 100000 nucleotides, about 10 to about 10000 nucleotides, about 10 to about 1000 nucleotides, about 10 to about 500 nucleotides, about 10 to about 300 nucleotides, about 10 to about 200 nucleotides, about 10 to about 100 nucleotides, about 20 to about 100000 nucleotides, about 20 to about 10000 nucleotides, about 20 to about 1000 nucleotides, about 20 to about 500 nucleotides, about 20 to about 300 nucleotides, about 20 to about 200 nucleotides, about 20 to about 100 nucleotides, about 30 to about 100000 nucleotides, about 30 to about 10000 nucleotides, about 30 to about 1000 nucleotides, about 30 to about 500 nucleotides, about 30 to about 300 nucleotides, about 30 to about 200 nucleotides, about 30 to about 100 nucleotides, about 50 to about 100000 nucleotides, about 50 to about 10000 nucleotides, about 50 to about 1000 nucleotides, about 50 to about 500 nucleotides, about 50 to about 300 nucleotides, about 50 to about 200 nucleotides, or about 50 to about 100 nucleotides.

[0124] Examples of molecules that are utilized as probes include, but are not limited to, RNA and DNA. In some embodiments, the term “probe” with regards to nucleic acids, refers to any molecule that is capable of selectively binding to a specifically intended target nucleic acid sequence. In some embodiments, probes are specifically designed to be labeled, for example, with a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, or other labels or tags. In some embodiments, the fluorescent label comprises a fluorophore. In some embodiments, the fluorophore is an aromatic or heteroaromatic compound. In some embodiments, the fluorophore is a pyrene, anthracene, naphthalene, acridine, stilbene, benzoxazole, indole, benzindole, oxazole, thiazole, benzothiazole, canine, carbocyanine, salicylate, anthranilate, xanthenes dye, coumarin. In some examples, xanthene dyes include, e.g., fluorescein and rhodamine dyes. Fluorescein and rhodamine dyes include, but are not limited to, 6- carboxyfluorescein (FAM), 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE), tetrachlorofluorescein (TET), 6-carboxyrhodamine (R6G), N,N,N; N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX). Suitable fluorescent probes also include the naphthylamine dyes that have an amino group in the alpha or beta position. For example, naphthylamino compounds include I-dimethylaminonaphthyl-5 -sulfonate, l-anilino-8-naphthalene sulfonate and 2-p-toluidinyl-6- naphthalene sulfonate, 5 -(2'-aminoethyl)aminonaphthalene-I -sulfonic acid (EDANS). In some examples, coumarins include, e.g., 3-phenyl-7-isocyanatocoumarin; acridines, such as 9-isothiocyanatoacridine and acridine orange; N-(p-(2-benzoxazolyl)phenyl) maleimide; cyanines, such as, e.g., indodicarbocyanine 3 (Cy3), indodicarbocyanine 5 (Cy5), indodicarbocyanine 5.5 (Cy5.5), 3-(-carboxy-pentyl)-3'-ethyl-5,5'- dimethyloxacarbocyanine (CyA); 1H, 5H, 11H, 15H-Xantheno[2,3, 4-ij: 5,6, 7-i'j']diquinolizin-18-ium, 9- [2 (or 4)-[[[6-[2,5-dioxo-I-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4 (or 2)-sulfophenyl]-2,3, 6,7,12,13, 16,17-octahydro-inner salt (TR or Texas Red); or BODIPY™ dyes. In some cases, the probe comprises FAM as the dye label.

[0125] In some embodiments, primers and / or probes for detecting a target nucleic acid are used in an amplification reaction. In some embodiments, the amplification reaction is qPCR. In an example, a qPCR is a method employing a TaqMan™ assay. In some embodiments, qPCR comprises using an intercalating dye. Examples of intercalating dyes include SYBR® green I, SYBR® green II, SYBR® gold, ethidium bromide, methylene blue, pyronin Y, 4',6-diamidino-2-phenylindole (DAPI), acridine orange, or phycoerythrin.

[0126] In one aspect, the methods provided herein for determining the presence, absence, and / or quantity of a nucleic acid sequence comprise an amplification reaction such as qPCR. In one embodiment, genetic material is obtained from a sample of a subject, e.g., a sample of blood or serum.

[0127] In an example qPCR assay, the nucleic acid sample is combined with primers and probes specific for a target nucleic acid that may or may not be present in the sample, and a DNA polymerase. An amplification reaction is performed with a thermal cycler that heats and cools the sample for nucleic acid amplification, and illuminates the sample at a specific wavelength to excite a fluorophore on the probe and detect the emitted fluorescence. For TaqMan™ methods, the probe may be a hydrolysable probe comprising a fluorophore and quencher that is hydrolyzed by DNA polymerase when hybridized to a target nucleic acid. In some cases, the presence of a target nucleic acid is determined when the number of amplification cycles to reach a threshold value is less than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, or 20 cycles.

[0128] In some embodiments, one target nucleic acid (e.g., a polymorphism) is detected with the methods disclosed herein. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 target nucleic acids are detected. In some embodiments, the at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 target nucleic acids are detected in a single multiplexed assay.

[0129] To practice the methods and systems provided herein, genetic material may be extracted from a sample obtained from a subject, e.g., a sample of blood or serum. In certain embodiments where nucleic acids are extracted, the nucleic acids are extracted using any technique that does not interfere with subsequent analysis. In certain embodiments, this technique uses alcohol precipitation using ethanol, methanol, or isopropyl alcohol. In certain embodiments, this technique uses phenol, chloroform, or any combination thereof. In certain embodiments, this technique uses cesium chloride. In certain embodiments, this technique uses sodium, potassium or ammonium acetate or any other salt commonly used to precipitate DNA. In certain embodiments, this technique utilizes a column or resin based nucleic acid purification scheme such as those commonly sold commercially, one non-limiting example is the GenElute™ Bacterial Genomic DNA Kit available from Sigma Aldrich. In certain embodiments, after extraction the nucleic acid is stored in water, Tris buffer, or Tris-EDTA buffer before subsequent analysis. In an example embodiment, the nucleic acid material is extracted in water. In some cases, extraction does not comprise nucleic acid purification. In certain embodiments, RNA may be extracted from cells usingRNA extraction techniques including, for example, using acid phenol / guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA preparation kits (Qiagen) or PAXgene (PreAnalytix, Switzerland).

[0130] In some embodiments, the sample is assayed to measure a presence, absence or quantity of one or more polymorphisms. In some embodiments, the sample is assayed to measure a presence, absence or quantity of at least two polymorphisms. In some embodiments, the sample is assayed to measure a presence, absence or quantity of at least three polymorphisms. In some embodiments, the sample is assayed to measure a presence, absence, or quantity of at least four polymorphisms. In some embodiments, the sample is assayed to measure a presence, absence, or quantity of at least five polymorphisms.

[0131] Any suitable approach may be used for detection or imputation of HLA genes. For imputation, the Michigan Imputation Server, imputationserver.sph.umich.edu, or any other suitable imputation software, e.g., HLA*IMP:02, HLA*IMP:03, SNP2HLA, HIBAG, CookHLA, or DEEP*HLA may be used). For additional information on HLA imputation, see, e.g., Naito et al. Semin. Immunopathol. 44(1): 15-28, 2022; Cook et al. Nat. Commun. 12, 1264. 2021 : and Nai to ct al. AW. Commun. 12, 1639, 2021.Methods of Detecting a Marker

[0132] In some embodiments, methods of detecting a presence, absence, or level of a target protein (e.g., biomarker) in the sample obtained from the subject involve detecting protein activity or expression. In some embodiments, the target protein is ANCA or antipseudomonas fluorescens-related protein (i2). A target protein may be detected by use of an antibody -based assay, where an antibody specific to the target protein is utilized. In some embodiments, antibody-based detection methods utilize an antibody that binds to any region of target protein. In one example, the method of analysis comprises performing an enzyme- linked immunosorbent assay (ELISA). The ELISA assay may be a sandwich ELISA or a direct ELISA. Another exemplary method of analysis comprises a single molecule array, e.g., Simoa®. Other examples of methods of detection include immunohistochemistry and lateral flow assay. Other examples of methods for detecting a target protein include, but are not limited to, gel electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, or various immunological methods such as fluid or gel precipitation reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassay (RIA), immunofluorescent assays, and Western blotting. In some embodiments, antibodies, or antibody fragments, are used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins. The antibody or protein can be immobilized on a solid support for Western blots and immunofluorescence techniques. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. In some embodiments, supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

[0133] In some cases, a target protein may be detected by detecting binding between the target protein and a binding partner of the target protein. In some embodiments, methods of analysis of protein-protein binding comprise performing an assay in vivo or in vitro, or ex vivo. In some embodiments, the method of analysis comprises an assay such as a co-immunoprecipitation (co-IP), pull-down, crosslinking protein interaction analysis, labeled transfer protein interaction analysis, or Far-western blot analysis, Forster resonance energy transfer (FRET) based assay, including, for example FRET-fluorescence lifetime imaging (FLIM), a yeast two-hybrid assay, bimolecular fluorescence complementation (BiFC), or split luciferase assay.

[0134] Disclosed herein are methods of detecting a presence or a level of one or more serological markers in a sample obtained from a subject. In some embodiments, the one or more serological markers comprises anti-Saccharomyces cerevisiae antibody (ASCA), an anti-neutrophil cytoplasmic antibody (ANCA), anti-i2 antibody, antibody against E.coli outer membrane porin protein C (anti-OmpC), antichitin antibody, pANCA antibody, and anti-Cbirl flagellin antibody. In some embodiments, the antibodies comprises immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin E (IgE), or immunoglobulin M (IgM), immunoglobulin D (IgD), or a combination thereof. Any suitable method for detecting a target protein or biomarker disclosed herein may be used to detect a presence, absence, or level of a serological marker. In some embodiments, the presence or the level of the one or more serological markers is detected using an ELISA, a single molecule array (e.g., Simoa®), immunohistochemistry, internal transcribed spacer (ITS) sequencing, or any combination thereof. In some embodiments, the ELISA is a fixed leukocyte ELISA. In some embodiments, the ELISA is a fixed neutrophil ELISA. A fixed leukocyte or neutrophil ELISA may be useful for the detection of certain serological markers, such as those described in Saxon et al., J. Allergy Clin. Immuno. 86:2; 202-210 (August 1990). In some embodiments, ELISA units (EU) are used to measure positivity of a presence or level of a serological marker (e.g., seropositivity or seronegativity), which reflects a percentage of a standard or reference value. In some embodiments, the standard comprises pooled sera obtained from well-characterized patient population (e.g., diagnosed with the same disease or condition the subject has, or is suspected of having) reported as being seropositive for the serological marker of interest. In some embodiments, measuring seropositivity or seronegativity comprises calculating a percentage of a reference value from pooled sera obtained from a patient population diagnosed with IBD. In some embodiments, the control or reference value comprises 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 EU. In some embodiments, a quartile sum scores are calculated using, for example, the methods reported in Landers et al., Gastroenterology (2002)123:689-699.Pharmaceutical Compositions, Formulations and Methods of Administration

[0135] In one aspect, methods of treating a subject, e.g., a subject having an inflammatory disease such as IBD, involve administration of a pharmaceutical composition comprising a therapeutic agent described herein, e.g., one or more thiopurine drugs, one or more additional therapeutic agents, or a combinationthereof, in therapeutically effective amounts to said subject. In some embodiments, a therapeutic agent described herein is used in the preparation of medicaments for treating an inflammatory disease, such as IBD (e.g., CD or UC).

[0136] In certain embodiments, the compositions containing the therapeutic agent described herein are administered for prophylactic and / or therapeutic treatments. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician.

[0137] In prophylactic applications, compositions containing a therapeutic agent described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition, e.g., an inflammatory disease, such as IBD (e.g., Crohn’s Disease or ulcerative colitis). Such an amount is defined to be a “prophylactically effective amount or dose.” In this use, the precise amounts also depend on the patient's state of health, weight, and the like. When used in a patient, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.

[0138] In certain embodiments wherein the patient’s condition does not improve, upon the doctor’s discretion the administration of therapeutic agent is administered chronically, that is, for an extended period of time, including throughout the duration of the patient’s life in order to ameliorate or otherwise control or limit the symptoms of the patient’s disease or condition.

[0139] In certain embodiments wherein a patient’s status does improve, the dose of therapeutic agent being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”). In specific embodiments, the length of the drug holiday is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction during a drug holiday is, by way of example only, by 10%- 100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.

[0140] In certain embodiments, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug diversion”). In specific embodiments, the length of the drug diversion is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction during a drug diversion is, by way of example only, by 10%- 100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%. After a suitable length of time, the normal dosing schedule is optionally reinstated.

[0141] In some embodiments, once improvement of the patient's conditions has occurred, a maintenancedose is administered if necessary. Subsequently, in specific embodiments, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the patient requires intermittent treatment on a long-term basis upon any recurrence of symptoms.

[0142] The amount of a given therapeutic agent that corresponds to such an amount varies depending upon factors such as the particular therapeutic agent, disease condition and its severity, the identity (e.g., weight, sex, age) of the subject in need of treatment, but can nevertheless be determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated. In general, however, doses employed for adult human treatment are typically in the range of 0.01 mg-5000 mg per day. In one aspect, doses employed for adult human treatment are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.

[0143] In some embodiments, as a patient is started on a regimen of a therapeutic agent, the patient is also weaned off (e.g., step-wise decrease in dose) a second treatment regimen.

[0144] In one embodiment, the daily dosages appropriate for a therapeutic agent herein are from about 0.01 to about 10 mg / kg per body weight. In specific embodiments, an indicated daily dosage in a large mammal, including, but not limited to, humans, is in the range from about 0.5 mg to about 1000 mg, conveniently administered in divided doses, including, but not limited to, up to four times a day. In some embodiments, the daily dosage is administered in extended-release form. In certain embodiments, suitable unit dosage forms for oral administration comprise from about 1 to 500 mg active ingredient. In some embodiments, the daily dosage or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regimen. In various embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the therapeutic agent used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.

[0145] With respect to a thiopurine drug, any suitable dose may be used. For example, in some embodiments, a dose of about 0.25-5 mg / kg / day of a thiopurine drug may be used. In other embodiments, a dose of about 0.75-2.5 mg / kg / day (e.g., about 0.75 mg / kg / day, about 1.0 mg / kg / day, about 1.25 mg / kg / day, about 1.5 mg / kg / day, about 1.75 mg / kg / day, about 2.0 mg / kg / day, about 2.25 mg / kg / day, or about 2.5 mg / kg / day) of a thiopurine drug is used. In some examples, the dose is about 1.5-2.5 mg / kg / day for azathioprine and 0.75-1.5 mg / kg / day for 6-mercaptopurine. In some examples, a subject may be screened for TPMT polymorphisms, e.g., prior to administration of one or more thiopurine drugs to the subject. In some examples, a heterozygote / carrier may be administered AZA at a dose of about 1 - 1.25 mg / kg / day, or MP at a dose of 0.5-0.75 mg / kg / day. For subjects with normal / high TPMT, thesubject may be administered AZA at a dose of about 2-2.5 mg / kg / day or MP at a dose of 1-1.5 mg / kg / day. The subject may be monitored for thiopurine levels and / or toxicity from the one or more thiopurine drugs, and the dosage of the one or more thiopurine drug may be adjusted. Additional guidance regarding dosing and monitoring of thiopurine drugs for IBD treatment is provided, e.g., in Warner et al. Front. Gastroenterol. 9( 1 ) : 10- 15 , 2018 and Lim et al . Front. Pharmacol. 9: 1107, 2018.

[0146] Toxicity and therapeutic efficacy of such therapeutic regimens may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 and the ED50. The dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD50 and ED50. In certain embodiments, the data obtained from cell culture assays and animal studies are used in formulating the therapeutically effective daily dosage range and / or the therapeutically effective unit dosage amount for use in mammals, including humans. In some embodiments, the daily dosage amount of the therapeutic agent described herein lies within a range of circulating concentrations that include the ED50 with minimal toxicity. In certain embodiments, the daily dosage range and / or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.

[0147] Disclosed herein are therapeutic agents formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active therapeutic agent into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins, 1999), herein incorporated by reference for such disclosure.

[0148] Provided herein are pharmaceutical compositions that include a therapeutic agent described herein (e.g., a thiopurine drug, one or more additional therapeutic agents, or a combination thereof), and at least one pharmaceutically acceptable inactive ingredient. In some embodiments, the therapeutic agents described herein are administered as pharmaceutical compositions in which the therapeutic agents are mixed with other active ingredients, as in combination therapy. In some embodiments, the pharmaceutical compositions include other medicinal or pharmaceutical agents, carriers, adjuvants, preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and / or buffers. In some embodiments, the pharmaceutical compositions include other therapeutically valuable substances.

[0149] A pharmaceutical composition, as used herein, refers to a mixture of a therapeutic agent, with other chemical components (i.e., pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, fdling agents, suspending agents, flavoring agents, sweetening agents, disintegratingagents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof. Optionally, the compositions include two or more therapeutic agents as described herein. In practicing the methods of treatment or uses provided herein, therapeutically effective amounts of therapeutic agents described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated, e.g., an inflammatory disease, fibrostenotic disease, and / or fibrotic disease. In some embodiments, the mammal is a human. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the therapeutic agent used and other factors. The therapeutic agents can be used singly or in combination with one or more therapeutic agents as components of mixtures.

[0150] The pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular), intranasal, buccal, topical, or transdermal administration routes. The administration may be systemic or local. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.

[0151] Pharmaceutical compositions including a therapeutic agent are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

[0152] The pharmaceutical compositions may include at least a therapeutic agent as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In addition, the methods and pharmaceutical compositions described herein include the use of N-oxides (if appropriate), crystalline forms, amorphous phases, as well as active metabolites of these compounds having the same type of activity. In some embodiments, therapeutic agents exist in unsolvated form or in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the therapeutic agents are also considered to be disclosed herein.

[0153] In some embodiments, a therapeutic agent exists as a tautomer. All tautomers are included within the scope of the agents presented herein. As such, it is to be understood that a therapeutic agent or a salt thereof may exhibit the phenomenon of tautomerism whereby two chemical compounds that are capable of facile interconversion by exchanging a hydrogen atom between two atoms, to either of which it forms a covalent bond. Since the tautomeric compounds exist in mobile equilibrium with each other they may be regarded as different isomeric forms of the same compound.

[0154] In some embodiments, a therapeutic agent exists as an enantiomer, diastereomer, or othersteroisomeric form. The agents disclosed herein include all enantiomeric, diastereomeric, and epimeric forms as well as mixtures thereof.

[0155] In some embodiments, therapeutic agents described herein may be prepared as prodrugs. A “prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a therapeutic agent described herein, which is administered as an ester (the “prodrug”) to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the therapeutic agent. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the therapeutic agent.

[0156] Prodrug forms of the therapeutic agents, wherein the prodrug is metabolized in vivo to produce an agent as set forth herein are included. Prodrug forms of the herein described therapeutic agents, wherein the prodrug is metabolized in vivo to produce an agent as set forth herein are included. In some cases, some of the therapeutic agents described herein may be a prodrug for another derivative or active compound. In some embodiments described herein, hydrazones are metabolized in vivo to produce a therapeutic agent.

[0157] In certain embodiments, compositions provided herein include one or more preservatives to inhibit microbial activity. Suitable preservatives include, without limitation, mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

[0158] In some embodiments, formulations described herein benefit from antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w / v glycerol, (b) about 0. 1% to about 1% w / v methionine, (c) about 0.1% to about 2% w / v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w / v ascorbic acid, (f) 0.003% to about 0.02% w / v polysorbate 80, (g) 0.001% to about 0.05% w / v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.

[0159] The pharmaceutical compositions described herein may be formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries,suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations. In one aspect, a therapeutic agent as discussed herein, e.g., therapeutic agent is formulated into a pharmaceutical composition suitable for intramuscular, subcutaneous, or intravenous injection. In one aspect, formulations suitable for intramuscular, subcutaneous, or intravenous injection include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In some embodiments, formulations suitable for subcutaneous injection also contain additives such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. In some cases, it is desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.

[0160] For intravenous injections or drips or infusions, a therapeutic agent described herein may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients.

[0161] Parenteral injections may involve bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative. The pharmaceutical composition described herein may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. In one aspect, the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0162] For administration by inhalation, a therapeutic agent may be formulated for use as an aerosol, a mist or a powder. Pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbondioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the therapeutic agent described herein and a suitable powder base such as lactose or starch.

[0163] Representative intranasal formulations are described in, for example, U.S. Pat. Nos. 4,476,116, 5,116,817 and 6,391,452. Formulations that include atherapeutic agent are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, fluorocarbons, and / or other solubilizing or dispersing agents known in the art. See, for example, Ansel, H. C. et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995). Preferably these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients. These ingredients are known to those skilled in the preparation of nasal dosage forms and some of these can be found in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, 21st edition, 2005. The choice of suitable carriers is dependent upon the exact nature of the nasal dosage form desired, e.g., solutions, suspensions, ointments, or gels. Nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are optionally present. Preferably, the nasal dosage form should be isotonic with nasal secretions.

[0164] Pharmaceutical preparations for oral use may be obtained by mixing one or more solid excipient with one or more of the therapeutic agents described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents are added, such as the cross linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. In some embodiments, dyestuffs or pigments are added to the tablets or dragee coatings for identification or to characterize different combinations of active therapeutic agent doses.

[0165] In some embodiments, pharmaceutical formulations of a therapeutic agent are in the form of a capsules, including push fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches, and / or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active therapeutic agent is dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added. A capsule may be prepared, for example, by placing the bulk blend of the formulation of the therapeutic agent inside of a capsule. In some embodiments, the formulations (non-aqueous suspensions and solutions) are placed in a soft gelatin capsule. In other embodiments, theformulations are placed in standard gelatin capsules or non-gelatin capsules such as capsules comprising HPMC.

[0166] All formulations for oral administration are in dosages suitable for such administration. In one aspect, solid oral dosage forms are prepared by mixing a therapeutic agent with one or more of the following: antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, fdling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents. In some embodiments, the solid dosage forms disclosed herein are in the form of a tablet, (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder, a capsule, solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms, multiparticulate dosage forms, beads, pellets, granules. In other embodiments, the pharmaceutical formulation is in the form of a powder. Compressed tablets are solid dosage forms prepared by compacting the bulk blend of the formulations described above. In various embodiments, tablets will include one or more flavoring agents. In other embodiments, the tablets will include a film surrounding the final compressed tablet. In some embodiments, the film coating can provide a delayed release of a therapeutic agent from the formulation. In other embodiments, the film coating aids in patient compliance (e.g., Opadry® coatings or sugar coating). Film coatings including Opadry® typically range from about 1% to about 3% of the tablet weight. In some embodiments, solid dosage forms, e.g., tablets, effervescent tablets, and capsules, are prepared by mixing particles of a therapeutic agent with one or more pharmaceutical excipients to form a bulk blend composition. The bulk blend is readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. In some embodiments, the individual unit dosages include film coatings. These formulations are manufactured by conventional formulation techniques.

[0167] In another aspect, dosage forms include microencapsulated formulations. In some embodiments, one or more other compatible materials are present in the microencapsulation material. Exemplary materials include, but are not limited to, pH modifiers, erosion facilitators, anti-foaming agents, antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.

[0168] Liquid formulation dosage forms for oral administration are optionally aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002). In addition to therapeutic agent the liquid dosage forms optionally include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent. In some embodiments, the aqueous dispersion further includes a crystal -forming inhibitor.

[0169] In some embodiments, the pharmaceutical formulations described herein are self-emulsifying drug delivery systems (SEDDS). Emulsions are dispersions of one immiscible phase in another, usuallyin the form of droplets. Generally, emulsions are created by vigorous mechanical dispersion. SEDDS, as opposed to emulsions or microemulsions, spontaneously form emulsions when added to an excess of water without any external mechanical dispersion or agitation. An advantage of SEDDS is that only gentle mixing is required to distribute the droplets throughout the solution. Additionally, water or the aqueous phase is optionally added just prior to administration, which ensures stability of an unstable or hydrophobic active ingredient. Thus, the SEDDS provides an effective delivery system for oral and parenteral delivery of hydrophobic active ingredients. In some embodiments, SEDDS provides improvements in the bioavailability of hydrophobic active ingredients. Methods of producing selfemulsifying dosage forms include, but are not limited to, for example, U.S. Pat. Nos. 5,858,401, 6,667,048, and 6,960,563.

[0170] Buccal formulations that include a therapeutic agent are administered using a variety of formulations known in the art. For example, such formulations include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136. In addition, the buccal dosage forms described herein can further include a bioerodible (hydrolysable) polymeric carrier that also serves to adhere the dosage form to the buccal mucosa. For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.

[0171] For intravenous injections, a therapeutic agent is optionally formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. For other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients.

[0172] Parenteral injections optionally involve bolus injection or continuous infusion. Formulations for injection are optionally presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative. In some embodiments, a pharmaceutical composition described herein is in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and contain formulatory agents such as suspending, stabilizing and / or dispersing agents.

[0173] In various embodiments, the particles of a therapeutic agents and one or more excipients are dry blended and compressed into a mass, such as a tablet, having a hardness sufficient to provide a pharmaceutical composition that substantially disintegrates within less than about 30 minutes, less than about 35 minutes, less than about 40 minutes, less than about 45 minutes, less than about 50 minutes, less than about 55 minutes, or less than about 60 minutes, after oral administration, thereby releasing the formulation into the gastrointestinal fluid.

[0174] In other embodiments, a powder including a therapeutic agent is formulated to include one or more pharmaceutical excipients and flavors. Such a powder is prepared, for example, by mixing the therapeutic agent and optional pharmaceutical excipients to form a bulk blend composition. Additional embodiments also include a suspending agent and / or a wetting agent. This bulk blend is uniformly subdivided into unit dosage packaging or multi -dosage packaging units.

[0175] In still other embodiments, effervescent powders are also prepared. Effervescent salts have been used to disperse medicines in water for oral administration.

[0176] In some embodiments, the pharmaceutical dosage forms are formulated to provide a controlled release of a therapeutic agent. Controlled release refers to the release of the therapeutic agent from a dosage form in which it is incorporated according to a desired profile over an extended period of time. Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles. In contrast to immediate release compositions, controlled release compositions allow delivery of an agent to a subject over an extended period of time according to a predetermined profile. Such release rates can provide therapeutically effective levels of agent for an extended period of time and thereby provide a longer period of pharmacologic response while minimizing side effects as compared to conventional rapid release dosage forms. Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations.

[0177] In some embodiments, the solid dosage forms described herein are formulated as enteric coated delayed release oral dosage forms, i.e., as an oral dosage form of a pharmaceutical composition as described herein which utilizes an enteric coating to affect release in the small intestine or large intestine. In one aspect, the enteric coated dosage form is a compressed or molded or extruded tablet / mold (coated or uncoated) containing granules, powder, pellets, beads or particles of the active ingredient and / or other composition components, which are themselves coated or uncoated. In one aspect, the enteric coated oral dosage form is in the form of a capsule containing pellets, beads or granules, which include a therapeutic agent that are coated or uncoated.

[0178] Any coatings should be applied to a sufficient thickness such that the entire coating does not dissolve in the gastrointestinal fluids at pH below about 5, but does dissolve at pH about 5 and above. Coatings are typically selected from any of the following: Shellac - this coating dissolves in media of pH >7; Acrylic polymers - examples of suitable acrylic polymers include methacrylic acid copolymers and ammonium methacrylate copolymers. The Eudragit series E, L, S, RL, RS and NE (Rohm Pharma) are available as solubilized in organic solvent, aqueous dispersion, or dry powders. The Eudragit series RL, NE, and RS are insoluble in the gastrointestinal tract but are permeable and are used primarily for colonic targeting. The Eudragit series E dissolve in the stomach. The Eudragit series L, L-30D and S are insoluble in stomach and dissolve in the intestine; Poly Vinyl Acetate Phthalate (PVAP) - PVAP dissolves in pH >5, and it is much less permeable to water vapor and gastric fluids. Conventional coating techniques such as spray or pan coating are employed to apply coatings. The coating thickness must be sufficient to ensure that the oral dosage form remains intact until the desired site of topical delivery in the intestinal tract is reached.

[0179] In some embodiments, pharmaceutical formulations are provided that include particles of a therapeutic agent and at least one dispersing agent or suspending agent for oral administration to a subject. The formulations may be a powder and / or granules for suspension, and upon admixture with water, asubstantially uniform suspension is obtained.

[0180] In some embodiments, particles formulated for controlled release are incorporated in a gel or a patch or a wound dressing.

[0181] In one aspect, liquid formulation dosage forms for oral administration and / or for topical administration as a wash are in the form of aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002). In addition to the particles of a therapeutic agent, the liquid dosage forms include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent. In some embodiments, the aqueous dispersions can further include a crystalline inhibitor.

[0182] In some embodiments, the liquid formulations also include inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3 -butyleneglycol, dimethylformamide, sodium lauryl sulfate, sodium doccusate, cholesterol, cholesterol esters, taurocholic acid, phosphotidylcholine, oils, such as cottonseed oil, groundnut oil, com germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfiiryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.

[0183] Furthermore, pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate / dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.

[0184] Additionally, pharmaceutical compositions optionally include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.

[0185] Other pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury -containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

[0186] In one embodiment, the aqueous suspensions and dispersions described herein remain in a homogenous state, as defined in The USP Pharmacists' Pharmacopeia (2005 edition, chapter 905), for at least 4 hours. In one embodiment, an aqueous suspension is re -suspended into a homogenous suspension by physical agitation lasting less than 1 minute. In still another embodiment, no agitation is necessary tomaintain a homogeneous aqueous dispersion.

[0187] In some embodiments, a therapeutic agent is prepared as transdermal dosage form. In some embodiments, the transdermal formulations described herein include at least three components: (1) a therapeutic agent; (2) a penetration enhancer; and (3) an optional aqueous adjuvant. In some embodiments the transdermal formulations include additional components such as, but not limited to, gelling agents, creams and ointment bases, and the like. In some embodiments, the transdermal formulation is presented as a patch or a wound dressing. In some embodiments, the transdermal formulation further includes a woven or non-woven backing material to enhance absorption and prevent the removal of the transdermal formulation from the skin. In other embodiments, the transdermal formulations described herein can maintain a saturated or supersaturated state to promote diffusion into the skin.

[0188] In one aspect, formulations suitable for transdermal administration of a therapeutic agent described herein employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and / or dispersed in a polymer or an adhesive. In one aspect, such patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Still further, transdermal delivery of the therapeutic agents described herein can be accomplished by means of iontophoretic patches and the like. In one aspect, transdermal patches provide controlled delivery of a therapeutic agent. In one aspect, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the therapeutic agent optionally with carriers, optionally a rate controlling barrier to deliver the therapeutic agent to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

[0189] In further embodiments, topical formulations include gel formulations (e.g., gel patches which adhere to the skin). In some of such embodiments, a gel composition includes any polymer that forms a gel upon contact with the body (e.g., gel formulations comprising hyaluronic acid, pluronic polymers, poly(lactic-co-glycolic acid (PLGA)-based polymers or the like). In some forms of the compositions, the formulation comprises a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter which is first melted. Optionally, the formulations further comprise a moisturizing agent.

[0190] In certain embodiments, delivery systems for pharmaceutical therapeutic agents may be employed, such as, for example, liposomes and emulsions. In certain embodiments, compositions provided herein can also include an mucoadhesive polymer, selected from among, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid / butyl acrylate copolymer, sodium alginate and dextran.

[0191] In some embodiments, a therapeutic agent described herein may be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical therapeuticagents can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.Compositions and Kits

[0192] Disclosed herein are compositions useful for the detection of a genotype or biomarker in a sample obtained from a subject according to the methods described herein. Aspects disclosed herein provide compositions comprising a polynucleotide sequence comprising at least 10 but less than 50 contiguous nucleotides of rs746071566, or a polymorphism in LD to rs746071566, or reverse complements thereof, wherein the contiguous polynucleotide sequence comprises a detectable molecule. Aspects disclosed herein also provide compositions comprising a polynucleotide sequence comprising at least 10 but less than 50 contiguous nucleotides of HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof, or reverse complements thereof, wherein the contiguous polynucleotide sequence comprises a detectable molecule. In various embodiments, the detectable molecule comprises a fluorophore. In other embodiments, the polynucleotide sequences further comprise a quencher.

[0193] Also disclosed herein are compositions comprising an antibody or antigen-binding fragment that specifically binds to a target protein or serological marker (e.g., ASCA or i2) described herein, wherein the antibody or antigen -binding fragment comprises a detectable molecule. In various embodiments, the antibody comprises a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a Fab, a Fab’, a F(ab’)2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody, a diabody, a multispecific antibody, a dual specific antibody, an anti -idiotypic antibody, or a bispecific antibody. In some embodiments, the antibody or antigen-binding fragment comprises an IgG antibody, an IgM antibody, and / or an IgE antibody. In some embodiments, the detectable molecule comprises a fluorophore. In some embodiments, the antibody or antigen-binding fragment is conjugated to a paramagnetic particle (e.g., bead).

[0194] Disclosed herein, are kits useful for to detect the genotypes and / or biomarkers disclosed herein. In some embodiments, the kits disclosed herein may be used to diagnose and / or treat a disease or condition in a subject; or select a patient for treatment and / or monitor a treatment disclosed herein, e.g., treatment with one or more thiopurine drugs. In some embodiments, the kit comprises the compositions described herein, which can be used to perform the methods described herein. Kits comprise an assemblage of materials or components, including at least one of the compositions. Thus, in some embodiments the kit contains a composition including of the pharmaceutical composition, for the treatment of a disease or condition as described herein, including an inflammatory disease such as IBD (e.g., CD or UC). In other embodiments, the kit contains all of the components necessary and / or sufficient to perform an assay for detecting and measuring markers disclosed herein, including all controls, directions for performing assays, and any necessary software for analysis and presentation of results.

[0195] In some embodiments, the kits described herein comprise components for detecting the presence, absence, and / or quantity of a target nucleic acid and / or protein described herein. In some embodiments, the kit further comprises components for detecting the presence, absence, and / or quantity of a serological marker described herein. In some embodiments, the kit comprises the compositions (e.g., primers, probes, antibodies) described herein. The disclosure provides kits suitable for assays such as enzyme-linkedimmunosorbent assay (ELISA), single -molecular array (Simoa®), PCR, and qPCR. The exact nature of the components configured in the kit depends on its intended purpose. In some embodiments, the kit may comprise a detection agent configured to bind configured to bind or hybridize a nucleic acid encoding NUDT15 at a polymorphism position comprising rs746071566 or a proxy polymorphism position in linkage disequilibrium therewith as determined with an r2 of at least 0.85, or a combination thereof. In some embodiments, the kit may comprise a detection agent configured to bind configured to bind or hybridize a nucleic acid genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC- 12*02, or any combination thereof. In some embodiments, the kit comprises a detection agent configured to bind ANCA, i2, or combinations thereof.

[0196] In some embodiments, the kits described herein are configured for the purpose of treating and / or characterizing a disease or condition (e.g., an inflammatory disease such as IBD), or subclinical phenotype thereof (e.g., stricturing, penetrating, or stricturing and penetrating disease phenotypes) in a subject. In some embodiments, the kits described herein are configured for the purpose of identifying a subject with a high likelihood of experiencing a thiopurine-induced adverse event. In some embodiments, the kit is configured particularly for the purpose of treating mammalian subjects. In some embodiments, the kit is configured particularly for the purpose of treating human subjects. In further embodiments, the kit is configured for veterinary applications, treating subjects such as, but not limited to, farm animals, domestic animals, and laboratory animals. In some embodiments, the kit is configured to select a subject for a therapeutic agent, such as those disclosed herein. In some embodiments, the kit is configured to select a subject for treatment with a therapeutic agent disclosed herein. In one embodiment, a therapeutic agent is a TNF inhibitor, an IL23 inhibitor, an integrin inhibitor, a SI PR inhibitor, a TL1A inhibitor, a CD30L inhibitor, a JAK inhibitor, or an IL21 inhibitor.

[0197] Instructions for use may be included in the kit. Instructions may comprise instructions for a genotype or biomarker (e.g., a serological marker such as ANCA or i2) in a sample obtained from a subject, instructions for treatment of a subject, instructions for selection of a subject, instructions for selection of a therapeutic agent, or instructions for a diagnosis of a subject. In some embodiments, the kit comprises instructions for determining whether a subject having IBD is likely to experience a thiopurine- induced adverse event.

[0198] In some embodiments, the kit comprises instructions for reviewing of medical records of the subject for markers of a likelihood of thiopurine-induced adverse events.

[0199] Optionally, the kit also contains other useful components, such as diluents, buffers, pharmaceutically acceptable carriers, syringes, catheters, applicators, pipetting or measuring tools, bandaging materials, or other useful paraphernalia. The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example, the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures. The components are typically contained in suitable packaging material(s). As employed herein, the phrase “packaging material” refers to one or morephysical structures used to house the contents of the kit, such as compositions and the like. The packaging material is constructed by well-known methods, preferably to provide a sterile, contaminant-free environment. The packaging materials employed in the kit are those customarily utilized in gene expression assays and in the administration of treatments. As used herein, the term “package” refers to a suitable solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding the individual kit components. Thus, for example, a package can be a glass vial or prefdled syringes used to contain suitable quantities of the pharmaceutical composition. The packaging material has an external label which indicates the contents and / or purpose of the kit and its components.Systems

[0200] Disclosed herein are systems for predicting a likelihood of a thiopurine-induced adverse event in a subject having a disease or condition, including an inflammatory disease such as IBD (e.g., CD or UC). In some embodiments, the systems described herein comprise kits and compositions for detecting the biomarkers described herein, e.g., serological markers and / or genotypes described herein in a biological sample of a subject. The system may comprise a computer system or platform.

[0201] In some embodiments, disclosed herein is a system for predicting a likelihood of a thiopurine- induced adverse event in a subject having a disease or condition, including an inflammatory disease such as IBD (e.g., CD or UC), comprising: (a) a computer processing device, optionally connected to a computer network; and (b) a software module executed by the computer processing device to analyze a target nucleic acid sequence and / or a serological marker in a sample from a subject.

[0202] In some embodiments, disclosed herein is a system for predicting a likelihood of a thiopurine- induced adverse event in a subject having IBD, the system comprising: (a) a genotyping device for determining genotype data of a subject with IBD; and (b) one or more computer processors operably coupled to the genotyping device, wherein the one or more computer processors are individually or collectively configured to perform operations comprising: (i) receiving the genotype data from the genotyping device; and (ii) identifying, in the genotype data, a genotype that is predictive of the likelihood of a thiopurine-induced adverse event.

[0203] In some instances, the system comprises a central processing unit (CPU), memory (e.g., random access memory, flash memory), electronic storage unit, computer program, communication interface to communicate with one or more other systems, and any combination thereof. In some instances, the system comprises a genotype device, such as a sequencer, polymerase chain reaction (PCR) machine or a genotype array configured for detecting a genotype comprising (i) a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (ii) HUA-DQA1*2, HUA-DRB1*7, HUADPB1* 17, HUAC-12*02, or any combination thereof; or (iii) any combination of (i) and (ii). The system may be configured to perform HUA imputation, e.g., as described herein.

[0204] . In some instances, the system is coupled to a computer network, for example, the Internet, intranet, and / or extranet that is in communication with the Internet, a telecommunication, or data network. In some embodiments, the system comprises a storage unit to store data and information regarding anyaspect of the methods described in this disclosure. Various aspects of the system are a product or article or manufacture.

[0205] One feature of a computer program includes a sequence of instructions, executable in the digital processing device’s CPU, written to perform a specified task. In some embodiments, computer readable instructions are implemented as program modules, such as functions, features, Application Programming Interfaces (APIs), data structures, and the like, that perform particular tasks or implement particular abstract data types. In light of the disclosure provided herein, those of skill in the art will recognize that a computer program may be written in various versions of various languages.

[0206] The functionality of the computer readable instructions may be combined or distributed as desired in various environments. In some instances, a computer program may comprise one sequence of instructions or a plurality of sequences of instructions. A computer program may be provided from one location. A computer program may be provided from a plurality of locations. In some embodiment, a computer program includes one or more software modules. In some embodiments, a computer program includes, in part or in whole, one or more web applications, one or more mobile applications, one or more standalone applications, one or more web browser plug-ins, extensions, add-ins, or add-ons, or combinations thereof.Web Application

[0207] In some embodiments, a computer program includes a web application. In light of the disclosure provided herein, those of skill in the art will recognize that a web application may utilize one or more software frameworks and one or more database systems. A web application, for example, may be created upon a software framework such as Microsoft® .NET or Ruby on Rails (RoR). A web application, in some instances, utilizes one or more database systems including, by way of non-limiting examples, relational, non-relational, feature oriented, associative, and XML database systems. Suitable relational database systems include, by way of non-limiting examples, Microsoft® SQL Server, mySQL™, and Oracle®. Those of skill in the art will also recognize that a web application may be written in one or more versions of one or more languages. In some embodiments, a web application is written in one or more markup languages, presentation definition languages, client-side scripting languages, server-side coding languages, database query languages, or combinations thereof. In some embodiments, a web application is written to some extent in a markup language such as Hypertext Markup Language (HTML), Extensible Hypertext Markup Language (XHTML), or extensible Markup Language (XML). In some embodiments, a web application is written to some extent in a presentation definition language such as Cascading Style Sheets (CSS). In some embodiments, a web application is written to some extent in a client-side scripting language such as Asynchronous Javascript and XML (AJAX), Elash® Actionscript, Javascript, or Silverlight®. In some embodiments, a web application is written to some extent in a server-side coding language such as Active Server Pages (ASP), ColdFusion®, Perl, Java™, JavaServer Pages (JSP), Hypertext Preprocessor (PHP), Python™, Ruby, Tel, Smalltalk, WebDNA®, or Groovy. In someembodiments, a web application is written to some extent in a database query language such as Structured Query Language (SQL). A web application may integrate enterprise server products such as IBM® Lotus Domino®. A web application may include a media player element. A media player element may utilize one or more of many suitable multimedia technologies including, by way of non -limiting examples, Adobe® Flash®, HTML 5, Apple® QuickTime®, Microsoft® Silverlight®, Java™, and Unity®.Mobile Application

[0208] In some instances, a computer program includes a mobile application provided to a mobile digital processing device. The mobile application may be provided to a mobile digital processing device at the time it is manufactured. The mobile application may be provided to a mobile digital processing device via the computer network described herein.

[0209] A mobile application is created by techniques known to those of skill in the art using hardware, languages, and development environments known to the art. Those of skill in the art will recognize that mobile applications may be written in several languages. Suitable programming languages include, by way of non-limiting examples, C, C++, C#, Featureive-C, Java™, Javascript, Pascal, Feature Pascal, Python™, Ruby, VB.NET, WML, and XHTML / HTML with or without CSS, or combinations thereof.

[0210] Suitable mobile application development environments are available from several sources. Commercially available development environments include, by way of non-limiting examples, AirplaySDK, alcheMo, Appcelerator®, Celsius, Bedrock, Flash Lite, .NET Compact Framework, Rhomobile, and WorkLight Mobile Platform. Other development environments may be available without cost including, by way of non-limiting examples, Lazarus, MobiFlex, MoSync, and Phonegap. Also, mobile device manufacturers distribute software developer kits including, by way of non-limiting examples, iPhone and iPad (iOS) SDK, Android™ SDK, BlackBerry® SDK, BREW SDK, Palm® OS SDK, Symbian SDK, webOS SDK, and Windows® Mobile SDK.

[0211] Those of skill in the art will recognize that several commercial forums are available for distribution of mobile applications including, by way of non-limiting examples, Apple® App Store, Android™ Market, BlackBerry® App World, App Store for Palm devices, App Catalog for webOS, Windows® Marketplace for Mobile, Ovi Store for Nokia® devices, Samsung® Apps, and Nintendo® DSi Shop.Standalone Application

[0212] In some embodiments, a computer program includes a standalone application, which is a program that may be run as an independent computer process, not an add-on to an existing process, e.g., not a plugin. Those of skill in the art will recognize that standalone applications are sometimes compiled. In some instances, a compiler is a computer program(s) that transforms source code written in a programming language into binary feature code such as assembly language or machine code. Suitable compiled programming languages include, by way of non-limiting examples, C, C++, Featureive-C, COBOL,Delphi, Eiffel, Java™, Lisp, Python™, Visual Basic, and VB .NET, or combinations thereof. Compilation may be often performed, at least in part, to create an executable program. In some instances, a computer program includes one or more executable complied applications.Web Browser Plug-In

[0213] A computer program, in some aspects, includes a web browser plug-in. In computing, a plug-in, in some instances, is one or more software components that add specific functionality to a larger software application. Makers of software applications may support plug-ins to enable third-party developers to create abilities which extend an application, to support easily adding new features, and to reduce the size of an application. When supported, plug-ins enable customizing the functionality of a software application. For example, plug-ins are commonly used in web browsers to play video, generate interactivity, scan for viruses, and display particular file types. Those of skill in the art will be familiar with several web browser plug-ins including, Adobe® Flash® Player, Microsoft® Silverlight®, and Apple® QuickTime®. The toolbar may comprise one or more web browser extensions, add-ins, or addons. The toolbar may comprise one or more explorer bars, tool bands, or desk bands.

[0214] In view of the disclosure provided herein, those of skill in the art will recognize that several plugin frameworks are available that enable development of plug-ins in various programming languages, including, by way of non-limiting examples, C++, Delphi, Java™, PHP, Python™, and VB .NET, or combinations thereof.

[0215] In some embodiments, Web browsers (also called Internet browsers) are software applications, designed for use with network -connected digital processing devices, for retrieving, presenting, and traversing information resources on the World Wide Web. Suitable web browsers include, by way of nonlimiting examples, Microsoft® Internet Explorer®, Mozilla® Firefox®, Google® Chrome, Apple® Safari®, Opera Software® Opera®, and KDE Konqueror. The web browser, in some instances, is a mobile web browser. Mobile web browsers (also called microbrowsers, mini-browsers, and wireless browsers) may be designed for use on mobile digital processing devices including, by way of non-limiting examples, handheld computers, tablet computers, netbook computers, subnotebook computers, smartphones, music players, personal digital assistants (PDAs), and handheld video game systems. Suitable mobile web browsers include, by way of non-limiting examples, Google® Android® browser, RIM BlackBerry® Browser, Apple® Safari®, Palm® Blazer, Palm® WebOS® Browser, Mozilla® Firefox® for mobile, Microsoft® Internet Explorer® Mobile, Amazon® Kindle® Basic Web, Nokia® Browser, Opera Software® Opera® Mobile, and Sony® PSP™ browser.Software Modules

[0216] The medium, method, and system disclosed herein may comprise one or more softwares, servers, and database modules, or use of the same. In view of the disclosure provided herein, software modules may be created by techniques known to those of skill in the art using machines, software, and languagesknown to the art. The software modules disclosed herein may be implemented in a multitude of ways. In some embodiments, a software module comprises a file, a section of code, a programming feature, a programming structure, or combinations thereof. A software module may comprise a plurality of files, a plurality of sections of code, a plurality of programming features, a plurality of programming structures, or combinations thereof. By way of non-limiting examples, the one or more software modules comprise a web application, a mobile application, and / or a standalone application. Software modules may be in one computer program or application. Software modules may be in more than one computer program or application. Software modules may be hosted on one machine. Software modules may be hosted on more than one machine. Software modules may be hosted on cloud computing platforms. Software modules may be hosted on one or more machines in one location. Software modules may be hosted on one or more machines in more than one location.Databases

[0217] The medium, method, and system disclosed herein may comprise one or more databases, or use of the same. In view of the disclosure provided herein, those of skill in the art will recognize that many databases are suitable for storage and retrieval of geologic profile, operator activities, division of interest, and / or contact information of royalty owners. Suitable databases include, by way of non-limiting examples, relational databases, non-relational databases, feature oriented databases, feature databases, entity-relationship model databases, associative databases, and XML databases. In some embodiments, a database is internet-based. In some embodiments, a database is web-based. In some embodiments, a database is cloud computing-based. A database may be based on one or more local computer storage devices.Data Transmission

[0218] The subject matter described herein, including methods for predicting a likelihood of a thiopurine- induced adverse event in a subject having an inflammatory disease such as IBD, are configured to be performed in one or more facilities at one or more locations. Facility locations are not limited by country and include any country or territory. In some instances, one or more steps are performed in a different country than another step of the method. In some instances, one or more steps for obtaining a sample are performed in a different country than one or more steps for detecting the presence or absence of a genotype or serological marker from a sample. In some embodiments, one or more method steps involving a computer system are performed in a different country than another step of the methods provided herein. In some embodiments, data processing and analyses are performed in a different country or location than one or more steps of the methods described herein. In some embodiments, one or more articles, products, or data are transferred from one or more of the facilities to one or more different facilities for analysis or further analysis. An article includes, but is not limited to, one or more components obtained from a subject, e.g., processed cellular material. Processed cellular materialincludes, but is not limited to, cDNA reverse transcribed from RNA, amplified RNA, amplified cDNA, sequenced DNA, isolated and / or purified RNA, isolated and / or purified DNA, and isolated and / or purified polypeptide. Data includes, but is not limited to, information regarding the stratification of a subject, and any data produced by the methods disclosed herein. In some embodiments of the methods and systems described herein, the analysis is performed and a subsequent data transmission step will convey or transmit the results of the analysis.

[0219] In some embodiments, any step of any method described herein is performed by a software program or module on a computer. In additional or further embodiments, data from any step of any method described herein is transferred to and from facilities located within the same or different countries, including analysis performed in one facility in a particular location and the data shipped to another location or directly to an individual in the same or a different country. In additional or further embodiments, data from any step of any method described herein is transferred to and / or received from a facility located within the same or different countries, including analysis of a data input, such as genetic or processed cellular material, performed in one facility in a particular location and corresponding data transmitted to another location, or directly to an individual, such as data related to the diagnosis, prognosis, responsiveness to therapy, or the like, in the same or different location or country.Business Methods Utilizing a Computer

[0220] The methods may utilize one or more computers. The computer may be used for managing customer and sample information such as sample or customer tracking, database management, analyzing genotype data, analyzing serological marker data, analyzing cytological data, storing data, billing, marketing, reporting results, storing results, or a combination thereof. The computer may include a monitor or other graphical interface for displaying data, results, billing information, marketing information (e.g., demographics), customer information, or sample information. The computer may also include means for data or information input. The computer may include a processing unit and fixed or removable media or a combination thereof. The computer may be accessed by a user in physical proximity to the computer, for example via a keyboard and / or mouse, or by a user that does not necessarily have access to the physical computer through a communication medium such as a modem, an internet connection, a telephone connection, or a wired or wireless communication signal carrier wave. In some cases, the computer may be connected to a server or other communication device for relaying information from a user to the computer or from the computer to a user. In some cases, the user may store data or information obtained from the computer through a communication medium on media, such as removable media. It is envisioned that data relating to the methods can be transmitted over such networks or connections for reception and / or review by a party. The receiving party can be but is not limited to an individual, a health care provider or a health care manager. In one embodiment, a computer-readable medium includes a medium suitable for transmission of a result of an analysis of a biological sample. The medium can include a result regarding a likelihood of experiencing a thiopurine-induced adverse event ofa subject, wherein such a result is derived using the methods described herein.

[0221] The entity obtaining a genotype or serological marker data may enter sample information into a database for the purpose of one or more of the following: inventory tracking, assay result tracking, order tracking, customer management, customer service, billing, and sales. Sample information may include, but is not limited to: customer name, unique customer identification, customer associated medical professional, indicated assay or assays, assay results, adequacy status, indicated adequacy tests, medical history of the individual, preliminary diagnosis, suspected diagnosis, sample history, insurance provider, medical provider, third party testing center or any information suitable for storage in a database. Sample history may include but is not limited to: age of the sample, type of sample, method of acquisition, method of storage, or method of transport.

[0222] The database may be accessible by a customer, medical professional, insurance provider, or other third party. Database access may take the form of electronic communication such as a computer or telephone. The database may be accessed through an intermediary such as a customer service representative, business representative, consultant, independent testing center, or medical professional. The availability or degree of database access or sample information, such as assay results, may change upon payment of a fee for products and services rendered or to be rendered. The degree of database access or sample information may be restricted to comply with generally accepted or legal requirements for patient or customer confidentiality.EXAMPLE

[0223] The following illustrative example is representative of embodiments of the systems and methods described herein and is not meant to be limiting in any way.Example 1 - Characterizing genetic associations and clinical parameters associated with adverse events of thiopurines in IBD patientsSubjects & Methods

[0224] Retrospective review of all IBD subjects attending adult and pediatric IBD Centers at Cedars- Sinai Medical Center from 2005 to 2022 was conducted. IBD subjects exposed to azathioprine or mercaptopurine were identified, and adverse IBD subjects exposed to azathioprine or mercaptopurine were identified based upon IBD physician assessment, and hematological and biochemical parameters. Adverse events included: bone marrow (BM) toxicity, leukopenia, pancreatitis, hepatotoxicity, gastrointestinal (GI) intolerance, arthralgia, rash / high fever / hypersensitivity etc. IBD-associated serologies were generated by ELISA (blinded to clinical outcomes).

[0225] Logistic Regression was used to determine associations between adverse events and demographic, clinical, and serological characteristics. HLA imputation was performed using Michigan Imputation Server. Whole exome sequencing (WES) was performed using Illumina platform and GATK best-practice variant calling and QC were performed following standard pipelines. Individual genetic variantassociation was assessed in Plink2 in European Ancestry Subjects by: Firth Regression and Logistic Regression, with Principal Components (PCs) for population stratification. Gene-based analyses were performed in SKAT.

[0226] The study cohort is summarized in the below table:Results

[0227] Clinical parameters associated with the adverse events of thiopurine drugs is summarized in the below table (Only P value <0.01 were included; ANCA, antinuclear cytoplasmic antibody; i2, antipseudomonas fluorescens-related protein):

[0228] HLA Alleles Associated with Adverse Events of Thiopurine are summarized in the below table:

[0229] FIG. 1 illustrates the dosage effect at DPB1* 17 on time from initiation of thiopurine drug treatment to development of pancreatitis.

[0230] Associations of genetic variants in NUDT15 with thiopurine-induced adverse events are summarized in the below table, in which 3 rare coding variants in NUDT15 are identified (Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566), rare - allele frequency 0.00078, no associations observed with adverse events):

[0231] A gene-based analysis of NUDT15 is shown in the below table, including the 2 known coding NUDT15 variants in a ‘global’ assessment of genetic variation association with adverse events, which highlights pleiotropic effects on adverse events.

[0232] The below table shows association of genetic variants in TPMT with thiopurine -induced adverse events. It is observed that there is no association between known TPMT coding variants and BM toxicity, Leukopenia, Pancreatitis, Rash / high fever / hypersensitivity, Hepatotoxicity, Flu-like symptom, or other adverse events.

[0233] A gene -based analysis of TPMT which includes the 3 known coding TPMT variants in a ‘global’ assessment of genetic variation association with adverse events is shown below:Conclusions

[0234] We found that age at diagnosis and serologic markers (ANCA, i2) were associated with thiopurine -associated adverse events.

[0235] We confirmed previous associations between thiopurine -induced adverse events with NUDT15 (leukopenia) and HLA (pancreatitis), however, we did not observe association between TPMT variants and leukopenia or bone marrow toxicity.

[0236] We observed pleiotropic effects for NUDT15 variants across the various phenotypes beyond those established by previous studies.

[0237] We identified a novel association between HLADPB1* 17 and thiopurine -induced pancreatitis.

[0238] Our findings provide additional evidence in support of recommendations to screen for these variants prior to starting a thiopurine.

[0239] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

CLAIMSWHAT IS CLAIMED IS:

1. A method of treating an inflammatory bowel disease (IBD) in a subject, the method comprising: administering to the subject a therapeutically effective amount of a thiopurine drug for the treatment of IBD, wherein the subject:(a) does not comprise a serological marker comprising antinuclear cytoplasmic antibody (ANCA), antipseudomonas fluorescens-related protein (i2), or any combination thereof;(b) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566);(c) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or(d) any combination thereof.

2. A method of determining whether a subject having IBD is likely to experience a thiopurine-induced adverse event, the method comprising:(a) detecting the presence of one or more of the following in the subject:(i) a serological marker comprising ANCA, i2, or any combination thereof;(ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566);(iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC- 12*02, or any combination thereof; or(iv) any combination thereof; and(b) determining a likelihood that the subject will experience a thiopurine -induced adverse event based, at least in part, on the presence of one or more of (i) - (iv) detected in the subject, wherein the likelihood is compared with a control subject having IBD but not having the presence of one or more of (i) - (iv) or having a lower risk as identified by another clinical method.

3. The method of claim 2, further comprising selecting a therapeutic agent for the treatment of IBD other than a thiopurine drug for the subject.

4. The method of claim 2 or 3, further comprising administering a therapeutically effective amount of a therapeutic agent for the treatment of IBD other than a thiopurine drug to the subject.

5. The method of any one of claims 1 -4, wherein the presence of the serological marker or the genotype is detected in a sample obtained from the subject.

6. A method of selecting a subject having IBD for treatment, the method comprising:(a) providing a sample from a subject having IBD to determine the presence of one or more of the following in the subject:(i) a serological marker comprising ANCA, i2, or any combination thereof;(ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566);(iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC- 12*02, or any combination thereof; or(iv) any combination thereof;(b) selecting a subject determined to comprise one or more of (i) - (iv); and(c) administering a therapeutically effective amount of a therapeutic agent for the treatment of IBD other than a thiopurine drug to the subject.

7. The method of claim 6, wherein the subject is determined to comprise two or more of (i) - (iv), three or more of (i) - (iv), or all of (i) - (iv).

8. A method of selecting a subject having IBD for treatment, the method comprising:(a) providing a sample from a subject having IBD to determine the presence of one or more of the following in the subject:(i) a serological marker comprising ANCA, i2, or any combination thereof;(ii) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566);(iii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC- 12*02, or any combination thereof; or(iv) any combination thereof;(b) selecting a subject determined to not comprise any of (i) - (iv); and(c) administering a therapeutically effective amount of thiopurine drug to the subject.

9. The method of any one of claims 5-8, wherein the sample comprises blood, serum, plasma, sweat, hair, tears, urine, saliva, stool, or a combination thereof.

10. The method of any one of claims 1-9, wherein the serological marker is detected by a method comprising an enzyme-linked immunosorbent assay (ELISA).

11. The method of claim 10, further comprising measuring seropositivity or seronegativity of the serological marker, optionally wherein the measuring the seropositivity or the seronegativity comprises calculating a percentage of a reference value from pooled sera obtained from a patient population diagnosed with IBD.

12. The method of any one of claims 1-11, wherein the genotype is detected by a method comprising detecting a nucleic acid sequence.

13. The method of claim 12, wherein the detecting the nucleic acid sequence comprises performing quantitative polymerase chain reaction (qPCR), nucleic acid sequencing, or hybridization to immobilized nucleic acid sequences on a nucleic acid array.

14. The method of any one of claims 3-13, wherein the therapeutic agent for the treatment of IBD other than a thiopurine drug comprises a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of tumor necrosis factor alpha (TNFa), an inhibitor of interleukin-23 (IL23), an inhibitor of integrin, an inhibitor of Sphingosine- 1 -phosphate receptor (S1PR), an inhibitor of TNF superfamily member 15 (TL1A), an inhibitor of CD30 ligand (CD30L), an inhibitor of Janus kinase 2 (JAK), an antagonist of interleukin-21 (IL21), or any combination thereof.

15. The method of any one of claims 1 and 4-14, further comprising administering one or more additional therapeutic agents to the subject.

16. The method of claim 15, wherein the one or more additional therapeutic agents comprise a glucocorticosteroid, thalidomide, cyclophosphamide, an inhibitor of TNFa, an inhibitor of IL23, an inhibitor of integrin, an inhibitor of S1PR, an inhibitor of TL1A, an inhibitor of CD30L, an inhibitor of JAK, an antagonist of IL21, or any combination thereof.

17. The method of claim 14 or 16, wherein:(a) the inhibitor of TNFa comprises adalimumab, infliximab, golimumab, certolizumab, or etanercept, or any combination thereof;(b) the inhibitor of IL23 comprises ustekinumab, guselkumab, risankizumab, brazikumab, mirikizumab, tildrakizumab, or briakinumab, or any combination thereof;(c) the inhibitor of integrin comprises etrolizumab, vedolizumab, natalizumab, or ontamalimab, or any combination thereof;(d) the inhibitor of SI PR comprises fmgolimod, siponimod, etrasimod, ozanimod, ponesimod, amiselimod, ceralifimod, or mocravimod, or any combination thereof;(e) the inhibitor of TL1A comprises tulisokibart, RVT-3101 / PF-06480605, or duvakitug, or any combination thereof; and / or(f) the antagonist of IL21 comprises an antibody or an antigen -binding fragment thereof.

18. The method of any one of claims 1-17, wherein the thiopurine comprises azathioprine, mercaptopurine, or thioguanine.

19. The method of any one of claims 1-18, wherein the thiopurine -induced adverse event comprises one or more of bone marrow (BM) toxicity, leukopenia, pancreatitis, hepatotoxicity, gastrointestinal (GI) intolerance, arthralgia, rash, high fever, and hypersensitivity.

20. A thiopurine drug for use in treating an IBD in a subject, wherein the subject:(a) does not comprise a serological marker comprising ANCA, i2, or any combination thereof;(b) does not comprise a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566);(c) does not comprise a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or(d) any combination thereof.

21. A therapeutic agent for the treatment of IBD other than a thiopurine drug for use in treating an IBD in a subject, wherein the subject comprises:(a) a serological marker comprising ANCA, i2, or any combination thereof;(b) a genotype comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566);(c) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or(d) any combination thereof.

22. A system for predicting a likelihood of a thiopurine-induced adverse event in a subject having IBD, the system comprising:(a) a genotyping device for determining genotype data of a subject with IBD; and(b) one or more computer processors operably coupled to the genotyping device, wherein the one or more computer processors are individually or collectively configured to perform operations comprising:(i) receiving the genotype data from the genotyping device; and(ii) identifying, in the genotype data, a genotype that is predictive of the likelihood of a thiopurine -induced adverse event.

23. The system of claim 22, wherein the genotype comprises (i) a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566); (ii) HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or any combination thereof; or (iii) any combination of (i) and (ii).

24. A kit for predicting a likelihood of a thiopurine -induced adverse event in a subject having IBD, the kit comprising:(a) one or more detection agents configured to bind or hybridize to (i) a polymorphism comprising a NUDT15 variant comprising Glyl7_Vall8del (13:48037782:AGGAGTC:A, rs746071566) or a proxy polymorphism in linkage disequilibrium (LD) therewith as determined with an r2 of at least 0.85, or a combination thereof, (ii) a genotype comprising HLA-DQA1*2, HLA-DRB1*7, HLADPB1* 17, HLAC-12*02, or a combination thereof, or (iii) multiple detection agents configured to bind or hybridize to both (i) and (ii); and(b) instructions for use of the detection agent to detect (i) the polymorphism or the proxy polymorphism in LD therewith, (ii) the genotype, or both (i) and (ii) in a sample obtained from the subject.

25. The kit of claim 24, further comprising:(a) a second detection agent configured to bind ANCA, i2, or a combination thereof, optionally wherein the second detection agent is an antibody; and(b) instructions for use of the second detection agent to detect seronegativity or seropositivity of the ANCA, the i2, or a combination thereof in a sample from the subject.

26. The kit of claim 24 or 25, wherein the instructions further comprise instructions for predicting the likelihood of a thiopurine -induced adverse event in the subject.

Citation Information

Patent Citations

  • Methods of diagnosing inflammatory bowel disease through rnaset2

    US20220162703A1

  • Composition for predicting risk of thiopurine-induced leukopenia, containing single nucleotide polymorphism marker within NUDT15 gene

    WO2015111852A1